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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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EXECUTIVE SUMMARY 
OBJECTIVES: To assess the appropriateness of the EQ-5D in 13 specified conditions (inflammatory 
bowel disease (IBD), epilepsy, diabetes, bowel cancer, head and neck cancer, psychological 
therapies, schizophrenia, dementia, cardiac arrhythmia, heart failure, coronary angioplasty, acute 
coronary syndrome, adult cardiac surgery); identify what measures may be used when the EQ-5D is 
not appropriate; identify if fields in corresponding National Clinical Audits (NCA) will suffice to 
conduct economic evaluations; present recommendations and future research questions in this 
area.  
METHOD: For each condition, three reviews were considered (WP1.1, 1.2 and 1.3). WP1.1 comprised 
a review of the appropriateness of the EQ-5D. Known reviews were assessed in the first instance for 
adequacy according to a set of criteria and expert opinion. Where a known review was not available 
or not adequate, a systematic review of systematic reviews was conducted. Where no adequate 
systematic review was identified, a systematic review of primary studies was conducted. For WP1.1, 
systematic searches were conducted in PubMed and Embase and two conference proceedings 
citation indexes (Web of Science and EuroQoL) using appropriate free-text keywords and 
MeSH/thesaurus terms, and applying appropriate limits according to the review being conducted 
(review of reviews or of primary studies).  WP1.2 comprised a review of condition specific measures 
that could be used and was only conducted for conditions where there was evidence that the EQ-5D 
was not adequate. This review consulted several online sources, such as Royal College websites, to 
identify research guidelines describing which condition specific measures should be used in 
research. WP1.3 comprised a review of existing cost-effectiveness evaluations used in recent health 
technology assessments (HTA) across the 13 conditions. Multiple technology appraisals (MTA) and 
single technology appraisals (STA) were systematically identified from the National Institute for 
Health and Care Excellence (NICE) HTA programme and the methods used to assess the cost 
effectiveness were extracted and compared to the data collected routinely in the NCAs.  
In all reviews, retrieved citations were considered for inclusion against a set of standardised 
selection criteria by one reviewer, and a second reviewer consulted in cases of uncertainty. 
Syntheses included tabulation of study results and either: presentation of a structured abstract and 
critique in the case of included systematic reviews or HTAs (WP1.1, 1.3); a narrative synthesis and 
discussion of results in the case of primary studies (WP1.1); or a tabulation and narrative synthesis in 
the case of research guidelines (WP1.2).  
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RESULTS:  
Patient reported outcome measures (WP1.1 and 1.2) 
For WP1.1, conclusions were drawn from known reviews in four cases (psychological therapies; 
diabetes; epilepsy children; dementia); from updates and reanalyses of existing reviews in five cases 
(epilepsy adults; bowel cancer; head and neck cancer; schizophrenia; CVD); and from systematic 
reviews of primary studies in two cases (IBD adults; IBD children). For WP1.2, six reviews of the 
literature, augmented with literature known to the authors, were used to identify alternative or 
additional patient reported outcome measures (PROMs) for patients with epilepsy (paediatrics), IBD 
(paediatrics), schizophrenia, head and neck cancer, dementia, and patients receiving psychological 
therapies. 
The psychometric properties of the EQ-5D were found to be adequate in ten of the 13 conditions. 
The exceptions were epilepsy (where the Paediatric quality of life inventory (PedsQL)TM was 
recommended), schizophrenia (where WEMWBS, to be replaced by ReQOL, was recommended) and 
dementia (where DEMQOL-U was recommended). 
With the exception of the mental health condition, no reference was made to the possibility of the 
EQ-5D being less responsive in older age groups.  The presence of comorbidities in subjects was not 
reported in either the existing reviews or most of the primary studies.  However, as the presence of 
comorbidities was not identified as an explicit exclusion criterion in all but the metal health review 
and in the diabetes studies, and the broad age ranges covered, it is assumed that the results and 
conclusions drawn will generalise across subjects with comorbidities. 
Evidence for use in economic evaluations (WP1.3) 
While the evidence collected in the individual audits will allow comparison of providers in many 
conditions, it is clear that the mandatory fields in most of the audits will not provide sufficient 
detailed information to perform formal economic evaluations.  However, many of the audits contain 
optional fields which would be useful for economic evaluations.  A recurrent issue relates to the 
level of detail collected and the timing of the variables collected.  To be useful for economic 
evaluations, the variables used have to be synchronised, and/or collected over periods of time to 
assess progression or relapse etc. 
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Recommendations and associated areas for future research 
There are two primary recommendations, namely a) develop a condition specific patient 
questionnaire for inclusion in the ten NCAs where PROMs are not currently collected, and b) expand 
the existing patient questionnaire to include additional settings such as primary care in diabetes and 
patients not undergoing ablation procedures in the cardiac arrhythmias NCA.  The EQ-5D-5L is 
recommended for inclusion in all audits except: schizophrenia (WEMWBS recommended, to be 
replaced with ReQOL), dementia (DEMQOL-U is recommended), and epilepsy (PedsQLTM is 
recommended).  In addition to the EQ-5D-5L, condition specific PROMs are recommended in several 
of the conditions (IBD, both cancers, patients receiving psychological therapies, dementia).  It is also 
recommended that mandatory information is collected relating to condition severity (IBD, cancer, 
epilepsy, diabetes, and CVD), current  interventions (all conditions), clinical events (all CVD 
conditions, diabetes) and mortality differentiated by cause (majority of conditions), and evidence 
relating to the side effects associated with pharmaceutical interventions and surgical/radiotherapy 
complications (all relevant conditions).   
Many of the suggestions for future research are generic across the conditions: 
 assess the psychometric properties of the recommended PROMs using the data collected in
the respective audits (all audits)
 synchronise the timing of collection of clinical and PROMs evidence to enable these data to
be used in economic evaluations (all audits)
 conduct a detailed review of data collected in the current audits with a view to informing
which variables should be collected as mandatory evidence to inform future economic
evaluations (all audits)
Individual condition specific recommendations and areas for future research include: 
 Conduct mapping functions between clinical variables/PROMs and preference-based
measures to enable the data to be used in economic evaluations (epilepsy, IBD, diabetes,
bowel cancer)
 Generate new preference-based weights for EQ-5D vision bolt-on (diabetes)
 Explore the effects of hypoglycaemic events on health related quality of life (HRQoL)
(diabetes)
 Ensure all therapists use a common set of measures, which match those adopted in the
National Health Service (NHS) Outcomes framework (psychological therapies)
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Acronym Definition 
AEs Adverse events 
BAI Beck Anxiety Inventory 
BCVA Best corrected visual activity 
BDI Becks depression index 
BMI Body mass index (kg/m2) 
CAI Clinical activity index   
CD Crohn’s disease 
CDAI Crohn’s disease activity index 
CHU-9D Child Health Utility 9D 
CORE-OM Clinical Outcomes in Routine Evaluation — Outcome Measure 
DH Department of Health 
DHP Diabetes health profile 
EQ-5D EuroQol 5 dimensions 
EQ-5D-Y EuroQol 5 dimensions youth version 
ERG Evidence review group 
FR Future research 
GAD-7 Generalised Anxiety Disorder Assessment-7 
HADS Hospital anxiety and depression scale 
HbA1c Glycated haemoglobin 
HRQoL Health related quality of life   
HTA Health technology assessment 
HUI Health Utility Index 
HUI2 Health Utility Index mark 2 
IBD Inflammatory bowel disease 
IBDQ Inflammatory bowel disease questionnaire 
MTA Multiple technology assessment 
NCA National Clinical Audit 
NHS National Health Service 
NHSSS National hospital seizure severity score 
NICE National Institute for Health and Care Excellence 
PedsQLTM Paediatric quality of life inventoryTM 
PHQ-9 Patient health questionnaire 
PR Potential recommendations 
PREMs Patient reported experience measures 
PROMs Patient reported outcome measures 
QALYs Quality adjusted life years 
QOLIE-AD-48 Quality of life in epilepsy for adolescents -48 
QOLIE-89 Quality of life in epilepsy -89 
R&D Research and development 
RR Relative risk 
SBP Systolic blood pressure 
SF-6D Short form 6 dimensions 
STA Single technology assessment 
TA Technology Appraisal 
UC Ulcerative colitis 
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UK United Kingdom 
UKPDS United Kingdom Prospective Diabetes Study 
WP Work package 
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1. BACKGROUND
EEPRU was approached by Jason Cox (Research & Development (R&D) Division) to prepare a 
programme of research to support the appropriateness of, and use of, patient reported outcome 
measures (PROMs) collected for the National Clinical Audit (NCA).  The EEPRU programme was 
informed by a R&D template prepared by Simon Bennett, Steve Fairman and Keith Willett at 
National Health Service (NHS) England. 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the NHS, 2) compare the cost-effectiveness 
of alternative providers in delivering the specific services (i.e. linking outcomes and resource use), 
and 3) assess the cost-effectiveness of alternative interventions and other changes in the NHS.  The 
intention is to introduce PROMs across a range of conditions over the next 3 years commencing with 
13 conditions in the 2014/15 NCA programme.  
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the Depeartment of Health (DH) (8th November 2013).  The current 
document provides an overview of the research conducted for Work Package 1 (WP1): to determine 
what PROMS should be used in the 13 health conditions specified in the 2014/15 NCA programme.   
Additional details of the methodologies used and the results for the individual conditions are 
provided in Appendices. 
2. OVERVIEW
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the EQ-5D is appropriate in the 13 health conditions specified in the 
2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
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Each component consists of a series of reviews of the literature.  A synopsis of the research is 
provided in the following sections with more detail on the individual review objectives, 
methodologies, and results provided in Appendices. 
3. METHOD
For each condition, three reviews were considered (WP1.1, 1.2 and 1.3). WP1.1 comprised a review 
of the appropriateness of the EQ-5D. In the first instance, a group of reviews known to the research 
team were assessed for adequacy according to a set of criteria and expert opinion (see Appendix A 
for more detail). For any given condition, where a known review was not available or not adequate, 
a recent systematic review of systematic reviews (Longworth et al. 2014b(1)) was consulted to 
identify other candidate systematic reviews for assessment of adequacy. Where no adequate 
systematic review was identified, a systematic review of primary studies was conducted.   
WP1.2 comprised a review of condition specific measures and was only conducted for conditions 
where there was evidence that the EQ-5D was not adequate. This review consulted several online 
sources, such as Royal College websites, to identify research guidelines describing which condition 
specific measures should be used.  The EQ-5D is designed for use in adults and it is not necessarily 
appropriate for paediatric populations.  As the epilepsy NCA collects data on paediatrics only, and 
the inflammatory bowel disease (IBD) NCA is likely to have a relatively large proportion of paediatric 
subjects, additional searches were conducted to identify evidence on the psychometric properties of 
known paediatric generic measures: EuroQol-5D youth version (EQ-5D-Y); child health utility 9D 
(CHU-9D); health utility index 2 (HUI2); and paediatric quality of life inventory (PedsQL)TM for these 
two conditions.(2-5) 
WP1.3 comprised a review of existing cost-effectiveness evaluations used in recent health 
technology assessments (HTA) across the 13 conditions. Multiple technology appraisals (MTA) and 
single technology appraisals (STA) were systematically identified from the National Institute for 
Health and Care Excellence (NICE) HTA programme and the methods used to assess the cost- 
effectiveness were extracted and compared to the data collected routinely in the National Clinical 
Audits.  
A summary of the results is provided below with additional detailed results for the individual 
conditions provided in Appendices C-K. 
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4. RESULTS FOR INFLAMMATORY BOWEL DISEASE
4.1 Evidence of appropriateness of EQ-5D in Inflammatory Bowel Disease (IBD) (WP1.1)
As no existing review was known or identified, a review of primary studies was conducted.  The 
searches identified just two studies (N=152;(6) N=502(7)) which satisfied the inlusion criteria.(6)-23)  
Both studies involved adults (≥17 years old) with either Crohn’s disease (CD) or ulcerative colitis 
(UC).  Both were conducted in Germany and just one used the required United Kingdom (UK) 
preference-based EQ-5D index.  
The EQ-5D was well accepted with less than 3.5% of EQ-5D responses missing (compared to 9% for 
the inflammatory bowel disease questionnaire (IBDQ)).  Althought there was some evidence of a 
potential ceiling effect, construct validity was generally good on all EQ-5D health dimensions (except 
self-care in patients with UC) when assessed against the disease activity indices, and when 
discriminating between those with active disease and those in remission.  Some problems were 
observed in the health dimensions pain/discomfort and anxiety/depression for outpatients compared 
to inpatients.  There was some evidence of the EQ-5D being a responsive measure in those with 
active disease (further away from full health) who reported a deterioration in health, but there may 
be problems with the EQ-5D’s responsiveness when detecting changes in less severely ill patients and 
those in remission.  However, small numbers of patients in the sub-group analyses made it difficult to 
draw robust conclusions.  In conclusion, the evidence supporting the appropriateness of the EQ-5D in 
adults with IBD is limited but fair but there is a lack of evidence relating to how appropriate the EQ- 
5D is for surgical health states.  Evidence is required in paediatrics, and in patients with more severe 
disease, both of which are relevant for the IBD NCA population (Table 1). 
4.2 Evidence of alternative measures in IBD (WP1.2) 
Searches identified no studies presenting evidence relating to the psychometric properties of the 
four pre-specified preference-based measures in paediatrics with IBD. However, eight articles, 
representing seven studies, which examined the psychometric properties of alternative measures 
were identified and reviewed.(8-15)  While primary research in this area appears to be growing, with 
evidence of development of several PROMs targeted at paediatrics with IBD, the evidence identified 
which could be used to compare PROMs in this population was limited.  The searches did not 
identify any evidence which could be used to generate quality adjusted life years (QALYs) in this 
population.  The most likely target measures for inclusion in the IBD NCA are the IMPACT-III and the 
PedsQLTM v4.  Based on the evidence reviewed, the target age group, and alternative responder 
versions, the PedsQLTM is recommended over IMPACT-III measure (Table 1).  However, research is 
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required to generate an associated preference-based tariff for the PedsQLTM (or a mapping function 
to one of the alternative preference-based generic measures) which could then be used to generate 
utility values for use in cost-effectiveness evaluations.  
Table 1: Summary of evidence on PROMs for IBD 
Measure (N) Target Age 
(years) 
Target 
Responder 
Acceptability Reliability Construct 
(KGV; 
Convergent) 
Responsiveness  
(Change over time; 
Ceiling effects) 
Adults 
EQ-5D (2) - - Good Good Good; Good Mixed; Mixed 
Acceptable but requires additional validation (n studies =2) particularly in patients with severe IBD and 
those undergoing surgical procedures.  Is not appropriate for paediatrics with IBD. 
PRO2, PRO3 (1) - - Very limited evidence available (n studies =1) 
Acceptable but requires additional validation and is only suitable for adults with CD (not for UC). 
Paediatrics 
IMPACT-III (3) ≥9 SR Good Good Mixed; Good No evidence 
Acceptable but requires additional validation (n studies = 3) and cannot be used to generate QALYs 
PedsQL (5) 2-18 SR;PR Good Good Good No evidence 
Acceptable (n studies = 5) but cannot be used to generate QALYs 
PedsQL GI 
module (1) 
  Good Good Good; No 
evidence 
No evidence; poor 
Acceptable, but very limited evidence (n studies = 1), would need to be used as an adjunct to the 
PedsQL core measure, and cannot be used to generate QALYs 
N=number of studies; KGV=known group validity; CE=ceiling effect; SR=self-report, PR=Parent/carer-report 
4.3 Evidence for economic evaluations in IBD (WP1.3) 
The recent HTAs for IBD evaluated interventions which are relevant to those provided to patients in 
the IBD NCA which gathers information from secondary care settings.  One compared  several 
pharmaceutical interventions for the treatment of moderate to severe CD or fistulising CD in both 
adult and paediatric populations,(16) and the second compared surgery (colectomy) with rescue 
therapy (standard care or alternative pharmaceutical interventions) for avoidance or delay of 
surgery and symptom free remission in hospitalised patients with acute exacerbation of UC.(17)  The 
key clinical information required to inform a standard economic evaluation comparing interventions 
(either anti-TNF agents, or surgical procedures) in IBD in the secondary care setting would be: 
condition severity, therapy regimens, the associated remission, relapse and withdrawal rates, the 
rates and types of surgical interventions and complications, and preference-based utility values.  
While the current IBD audit collects some information on the majority of these areas, there are 
some obvious omissions (see Appendix C).  One of the key issues is the timing of the data collection.  
As IBD is characterised by periods of ‘flares’ and remission; for the data to be useful for economic 
modelling purposes, the collection needs to be synchronised in terms of timing. 
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4.4 Recommendations for IBD 
In summary, the EQ-5D appears to be appropriate in adults with IBD, the PedsQL appears to be the 
most appropriate measure for paediatrics (although there are limitations with the usefulness of this 
measure for economic evaluations), and the current IBD audit collects much of the information 
required to conduct economic evaluations.  However there are caveats associated with these 
conclusions which require consideration.  The issues and corresponding potential recommendations 
(PR) and areas for future research (FR) are tabulated below (Table 2) with the corresponding 
narrative provided in Appendix C. 
Table 2: Recommendations and associated future research for IBD 
PR.1 Include the new version of the EQ-5D (EQ-5D-5L) in future adult patient questionnaires 
FR.1 Assess the psychometric properties of the EQ-5D-5L in adults with IBD using data collected 
in the audit 
PR.2 Include the PedsQLTM(and the PedsQLTM GI module) in future paediatric patient 
questionnaires 
FR.2 Investigate potential collaboration with the developers of the PedsQLTM with a view to 
developing a methodology to generate preference-based utility measures directly or 
indirectly (via mapping to alternative measure) from the PedsQLTM. 
PR.3 Include age related paediatric preference-based health related quality of life (HRQoL) 
instrument (e.g. CHU-9D, HUI2 and EQ-5D-Y) in future paediatric patient questionnaires 
FR.3 Assess the psychometric properties of the paediatric preference-based tools in IBD using 
data collected in the audit 
PR.4 Synchronise the timing of collection of a clinical measure (such as the Crohn’s disease 
activity index (CDAI) for patients with CD, or the clinical activity index (CAI) for patients 
with UC) and the HRQoL measure 
FR.4 Conduct analyses to generate mapping functions between the suggested clinical and 
preference-based measures to enable the evidence to be used in economic models 
PR.5 Include an additional PROM to capture disease severity, such as the PRO2 or PRO3 (and 
equivalent measures for UC and paediatrics), in the patient questionnaire 
FR.5 Assess the validity of the PRO2/PRO3 using data collected in the audit.  
FR.6 Conduct research to generate equivalent condition severity PROMs in adults and 
paediatrics with UC. 
PR.6 Include additional mandatory fields in the IBD audit such as response to current treatment, 
relapse and current disease activity (linked by time to HRQoL) 
FR.7 Detailed analyses of fields currently collected in the IBD audit to identify recommendations 
for future mandatory fields 
PR.7 Utilise links between the IBD audit and the new IBD register 
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5. RESULTS FOR EPILEPSY
5.1 Evidence of appropriateness of EQ-5D in epilepsy (WP1.1)
The epilepsy NCA is in paediatrics, consequently the EQ-5D, which is recommended for adults, is 
potentially not relevant for this population.  However, evidence from studies in adults will provide a 
useful indicator of the appropriateness of the EQ-5D in a younger population.  An existing systematic 
review was updated and a total of five studies (reported in seven publications) were included in the 
current review.(18-24)  The evidence base assessing the psychometric properties of the EQ-5D in 
adults with epilepsy on the whole is positive albeit limited.  There is some evidence of a ceiling effect 
compared to other generic measures (SF-6D and health utility index (HUI)).(23)  Support for 
construct validity was relatively good with evidence the EQ-5D was able to detect differences in sub-
groups categorised by seizure frequency,(19) and the National hospital seizure severity score 
(NHSSS),(88) despite the correlations between the EQ-5D and both the severity and control of 
seizures being small.(23)  While there was also no correlation between responses on the EQ-5D 
health dimensions and presence of comorbidity in one study,(23) a relationship between the EQ-5D 
anxiety/depression health dimension and hospital anxiety and depression scale (HADS) scores was 
reported.(24)  There was also evidence to suggest the EQ-5D was able to detect changes in HRQoL 
over time in patients sub-grouped by achievement of seizure reductions,(21) or improvement or 
deterioration on the global rating of change.(23)  However, one study suggested the magnitude of 
change in mean EQ-5D was smaller than might have been expected based on changes in the quality 
of life in epilepsy-89 (QOLIE-89) measure,(23) and in another study improvements in EQ-5D scores 
were not statistically significant in patients pre- versus post-surgery, where other measures 
were.(20)  In conclusion, the evidence suggests that the EQ-5D may not be the most appropriate 
measure in adults, though it may be regarded as adequate. However, the EQ-5D is not relevant for 
paediatrics, the subject of the epilepsy NCA.   
5.2 Alternative measures in epilepsy (WP1.2) 
Although limited, the evidence suggests the EQ-5D is adequate for adults, inferring the youth version 
is worth considering for paediatrics.  However, the EQ-5D-Y is only suitable for older children and no 
evidence was identified on its appropriateness in paediatrics with epilepsy.  The evidence identified 
which could be used to compare PROMs in this population was limited.  The searches, although 
limited in scope due to the time constraints of the project, did not identify any evidence which could 
be used to generate QALYs directly from PROMs in this population.  The most likely candidate 
measures for inclusion in the epilepsy NCA are the Quality of life in epilepsy for adolescents -48 
(QOLIE-AD-48) and the PedsQLTM v4.  Based on the evidence reviewed, the target age group, and 
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alternative responder versions, the PedsQLTM is recommended over QOLIE-AD-48 measure (Table 3).  
However, research is required to generate an associated preference-based tariff for the PedsQLTM 
(or a mapping function to one of the alternative preference-based generic measures) which could be 
used to generate utility values for use in cost-effectiveness evaluations.  
Table 3: Summary of evidence on PROMs for epilepsy 
Measure (N) Target 
Age 
(years) 
Target 
Responder 
Acceptability Reliability Construct 
(KGV; 
Convergent) 
Responsiveness  
(Change over time; 
Ceiling effects) 
Adults 
EQ-5D (5) - - No evidence No evidence Good; Good Mixed; Poor 
Adequate but the evidence on the different psychometric properties is limited (n studies =5) 
Is not appropriate for paediatrics with epilepsy. 
Paediatrics 
QOLIE-AD-48 
(3) 
11-17 SR No evidence Good Good; Mixed No evidence; Good 
Adequate but evidence is limited (n= 3 studies and not all properties tested) 
Would require a systematic literature review to identify additional evidence.  Cannot be used to 
generate QALYs and only appropriate for adolescents. 
PedsQL (5) 2-18 SR;PR No evidence Good Good; No 
evidence 
Unclear; no 
evidence 
Acceptable (n studies = 5) but cannot be used to generate QALYs 
PedsQL epilepsy module (1) 
Currently under development but could be considered in the future 
KGV = known group validity;  N = number of studies 
5.3 Evidence for economic evaluations in epilepsy (WP1.3) 
The economic models used in one STA and one clinical guideline (CG) were reviewed. The STA 
examined the clinical and cost-effectiveness of a pharmaceutical intervention in adults with partial 
refractory epilepsy,(25) while the CG compared interventions in primary and secondary care for both 
adults and children.(26)  It is worth noting that a) the results of the searches for preference-based 
utilities indicated that the volume of evidence in this patient group was sparse, particularly in 
paediatrics, and b) it was reported that utilities were a major driver of the cost-effectiveness 
results.(25) 
In summary, the existing HTA models were constructed around the number of seizures, the 
reduction in numbers of seizures (response) due to treatment, withdrawal from treatment due to 
adverse events (AEs), and HRQoL scores categorised by current health status.  The fields in the 
current NCA provide insufficient detailed mandatory information to examine changes in frequency 
of seizures, the epilepsy medications taken (and duration), or withdrawal due to AEs or non-
response.   The epilepsy patient questionnaire does not currently collect HRQoL information, 
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concentrating on patient reported experience measures (PREMs), and the mandatory fields do not 
include a surrogate measure which could be used to estimate proxy utility values.   It is not known if 
surgical interventions and associated information might be considered for collection in future audits 
but this is evidence that would be useful for comparing providers or the cost-effectiveness of 
alternative policies. While it is currently not possible to compare the cost-effectiveness of 
interventions in epilepsy using the audit data, it may be possible to compare performance across 
units.  
5.4 Recommendations for epilepsy 
In summary, the paediatric literature review indicates the PedsQL is an appropriate measure for 
paediatrics with epilepsy, but it cannot currently be used to generate utility values.   The results of 
the review of existing cost-effectiveness HTA models indicated that the evidence base of existing 
preference-based data in patients with epilepsy was extremely sparse, particularly in paediatrics, 
and that economic models are sensitive to the utility values used (see Appendix D).  Finally, the 
current epilepsy NCA does not provide sufficient mandatory information to compare providers or 
the cost-effectiveness of interventions as used in general clinical practice.  The issues and 
corresponding potential recommendations (PR) and areas for future research (FR) are tabulated 
below (Table 4) with the corresponding narrative provided in Appendix D. 
Table 4: Recommendations and associated future research for epilepsy 
PR.8 Include the PedsQLTM (and the PedsQLTM epilepsy module) in future epilepsy audits 
PR.9 Include age related paediatric preference-based HRQoL instrument (e.g. CHU-9D, HUI2 and 
EQ-5D-Y) in future paediatric audits 
FR.8 Assess the psychometric properties of the paediatric preference-based tools in epilepsy 
using data collected in the audit 
PR.10 Include additional mandatory fields in the epilepsy audit severity and frequency of seizures, 
response to current treatment, and medications (and if applicable, evidence relating to 
surgical interventions), linked by time to HRQoL. 
FR.9 Detailed analyses of fields currently collected in the epilepsy audit to identify 
recommendations for future mandatory fields 
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6 RESULTS FOR DIABETES 
6.1 Evidence of appropriatness of EQ-5D in diabetes (WP1.1) 
An existing systematic review was updated and 16 studies were included in the current 
review.(27;28)  The majority of studies appraised the UK EQ-5D tariff, and all used adult samples.  
Acceptability and reliability were both reported to be good.  There was some evidence of a ceiling 
effect in patients with diabetes, which may be more relevant in newly diagnosed patients who do 
not have diabetes related complications, and are thus more likely to score relatively high on the 
index. The majority of studies reported the construct validity of the EQ-5D was good when 
compared to diabetes specific clinical and quality of life measures. Exceptions included, for example, 
levels of visual acuity, and potentially glycated haemoglobin levels (HbA1c). Poor correlations against 
some variables are of less concern where the comparator may not reasonably be expected to 
produce a correlation with HRQoL. For example, the relationship between HbA1C and HRQoL is 
complex; HbA1c levels are an indication of blood glucose levels over the previous 2-3 months, 
whereas the EQ-5D asks patients what their HRQoL is today.  In conclusion, the EQ-5D is adequate in 
patients with diabetes but additional research is required before it can be recommended for 
patients with visual problems (Table 5).  
Table 5: Summary of evidence on EQ-5D for diabetes 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Adults 
EQ-5D (16) Good  Good  Good; Mixed Good; Poor 
Adequate, with exception of potential problems in patients with vision problems.  
6.2 Alternative measures in diabetes (WP1.2) 
Based on the psychometric properties of the EQ-5D reported for patients with diabetes, with the 
exception of potential problems in patients with vision problems, and the suggestion that there may 
be a ceiling effect, the evidence suggests the EQ-5D is appropriate in adults with diabetes. 
Consequently the evidence on other condition-specific or generic measures was not reviewed.  It is 
worth noting, however, that the NHS outcomes framework uses the Diabetes health profile (DHP) 
self-reported outcome measure in conjunction with the EQ-5D. The DHP is available in two forms, 
DHP-1 and DHP-18. DHP-18 takes less time to complete, is available in electronic formats as well as 
paper, and there is some limited evidence and ongoing research relating to its use in cost utility 
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analysis.(29) It aims to capture the impact of diabetes on everyday social and emotional functioning, 
which may not be captured by other measures.  
The problems with the EQ-5D in vision have been noted elsewhere.(30;31) and a bolt-on for vision 
has been developed. Patients are asked to select between “I have no problem seeing”; “I have some 
problems seeing” and “I have extreme problems seeing”. The impact of responses on the valuation 
of health states has been tested in an exploratory and a full valuation study.(31) The vision bolt-on 
has been shown to significantly impact on at least some health states, with complex interplay 
between severity of the vision response, and severity of responses in the other dimensions but the 
authors caution that further research with larger sample sizes is required.  
6.3 Evidence for economic evaluations in diabetes (WP1.3) 
The economic models in six STAs and one CG were reviewed.  Five of the studies compared 
insulin,(32-36) and the remaining two STAs compared interventions for diabetic related macular 
oedema.(37;38)  It was noted in several evidence review group (ERG) reports that the key areas of 
uncertainty in the models comparing insulin control were the HRQoL parameters used for 
hypoglycaemic events and treatment related changes in weight.  In the models exploring 
interventions for diabetes related visual acuity, the cost-effectiveness estimates were also noted to 
be sensitive to the utility values used.   
Diabetes is a complex disease and patients are at risk of multiple diabetes related complications.  
The existing HTA models comparing insulin therapies used the United Kingdom Prospective Diabetes 
Study (UKPDS) risk functions to model the benefits of treatments in terms of reductions in both 
micro and macrovascular complications.  The key variables (HbA1c, body mass index (BMI), systolic 
blood pressure (SBP)) required for the functions are noted as optional fields in the current core 
diabetes NCA (Appendix E).  While many of the variables required are not currently listed in the NCA, 
they may be available from GP records via the primary care audits.  The existing HTA models 
comparing interventions for diabetes related visual acuity use a clinical grading measure (e.g. best 
corrected visual activity (BCVA)) to describe health states within the model, and changes in these to 
represent the effectiveness of the intervention.  While the optional fields contain a field relating to 
eye screen attendance, there is no information which suggests that the results of eye screens are 
recorded in the NCA, or that presence or severity of macular oedema is recorded. 
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No patient reported outcome measures are currently collected in the core diabetes NCA and while it 
is understood that there will be some data on patients’ experience of services collected in 
subsequent audits, there are currently no fields relating to HRQoL or any alternative measure which 
could be used to generate the preference-based data required to inform cost-effectiveness models.  
However, depending on the level of responses collected in the inpatient audit, with additional fields 
added, it is possible that the diabetes NCA could be used to compare providers and the cost-
effectiveness of interventions.   
6.4 Recommendations for diabetes  
In general, the EQ-5D appears to be adequate in patients with diabetes, and based on the 
assumption that the audit can be linked to patients’ primary care records, the current IBD audit 
collects much of the information required to conduct economic evaluations.  The exceptions in both 
cases are in patients with visual problems, and information relating to HbA1c and hypoglycaemic 
events.  Potential recommendations (PR) and areas for future research (FR) are tabulated below 
(Table 6) with the corresponding narrative provided in Appendix E. 
Table 6: Recommendations and associated future research for diabetes 
PR.11 Include the new version of the EQ-5D (EQ-5D-5L) and the DHP in future adult patient 
questionnaires 
FR.10 Assess the psychometric properties of the EQ-5D-5L and the DHP in adults with diabetes 
using data collected in the audit 
PR.12 Include the vision  bolt-on to the EQ-5D for patients with vision problems 
FR.11 Conduct a study to generate preference-weights for the EQ-5D vision bolt-on 
PR.13 Include a clinical measure such as the BCVA or  vision acuity score in the audit (collected at 
the same time as the HRQoL variable) 
FR.12 Conduct a study exploring the effect on HRQoL associated with hypoglycaemic events and 
the associated fear of future events using data collected in the audit 
PR.14 Include paediatric preference-based HRQoL instruments (e.g. CHU-9D and the HUI2 or 
PedsQL) in future paediatric questionnaires 
FR.13 Assess the psychometric properties of the paediatric preference-based tools in paediatrics 
with diabetes using data collected in the audit 
FR.14 Detailed analyses of fields currently collected in the IBD audit to identify recommendations 
for future mandatory fields 
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7 RESULTS FOR BOWEL CANCER 
7.1 Evidence of appropriateness of EQ-5D in bowel cancer (WP1.1) 
An existing systematic review was updated and nine studies were included in the current 
review.(31;39)  All involved patients with colorectal cancer (no information on age distribution).  In 
seven studies patients were undergoing or had recently undergone surgery,(168- 173) whilst in two 
studies patients received a pharmaceutical intervention.(40;41) With the exception of one study 
which used UK preference-based weights,(40) it is unclear which tariff was used.  
No evidence was reported in the review for either acceptability or reliability of the EQ-5D.  Construct 
validity was explored using known group methods in six studies, and convergent methods in one 
study. The evidence relating to construct validity by known group methods was mixed, with two 
studies reporting that the EQ-5D was able to detect differences between groups where other 
measures did,(42;43) two studies reporting that the EQ-5D failed to detect a difference in groups 
where other measures did,(44;45) one study reporting no differences between groups by the EQ-5D 
and EORTC QLQ-C30(46) and one study reporting no difference in EQ-5D scores between two groups 
where it was not clear if a difference should be expected.(47)  The evidence-base relating to 
convergent validity was small with only one relatively small (n=104) study examining this. Results 
relating to responsiveness were also mixed, with one study showing the EQ-5D was able to detect a 
change where another measure, (7) two studies showing the EQ-5D was not able to detect a change 
where other measures did,(43;48) and two studies showing mixed results where the EQ-5D was able 
to detect some changes but not others.(41;46)  In summary, whilst there is some strong positive 
evidence to support the use of the EQ-5D in this patient group, the negative and mixed evidence 
suggest that additional validation is required before the EQ-5D can be recommended (Table 7).  
Table 7: Summary of evidence on EQ-5D for bowel cancer 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Adults 
EQ-5D (9) Not reported Not reported Mixed; Poor (n=1) Mixed; Not reported 
EQ-5D requires additional validation. 
7.2 Alternative measures in bowel cancer (WP1.2) 
It is recommended that a cancer specific PROM, the European Organization Quality of Life 
Questionnaire (EORTC QLQ-C30) and its relevant bowel-specific module EORTC CR29 is collected 
alongside the EQ-5D as condition specific measures may be more sensitive to the effects of 
interventions on the condition specific symptoms and the side effects of treatments.  The EORTC 
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QLQ-C30 consists of 30 questions covering function (e.g. cognitive, emotional, physical, role, social) 
and the common cancer symptoms (e.g. fatigue, nausea and vomiting, pain).(49) Responses to these 
are summarised using 14 sub-scales plus a global quality of life scale.(49)  A recently developed UK 
based preference-based utility tariff can be used to generate utility values for use in economic 
evaluations.(50)  However, it should be noted that the the utility values obtained using this tariff are 
not directly comparable to those generated using the EQ-5D.    
7.3 Evidence for economic evaluations in bowel cancer (WP1.3) 
Economic models in six HTAs and one CG were reviewed.(51-55) The majority examined the clinical 
and cost-effectiveness of chemotherapy with just one study comparing laparoscopic surgery with 
open-resection.(56)  The results of the searches conducted to inform the model parameters suggest 
the volume of EQ-5D data in patients with colorectal cancer is very limited with many of the authors 
recommending this as a future research priority.  It has also been suggested that evidence 
categorised by Duke’s stage would be useful.  Staging is currently used for chemotherapy licensing 
indications consequently this information would be useful when modelling the cost-effectiveness of 
screening interventions; it could be linked to audit data to estimate resource usage by stage; and if 
stage was linked to EQ-5D utility values this could be used to populate future economic models in 
bowel cancer.   
The NCA information on clinical interventions (tumour, treatment, follow-up) would provide some of 
the information required to compare alternative treatments.  The mortality date could be used to 
model overall mortality, and there may be sufficient detail to extract survival curves for progression 
and recurrence from the mandatory fields.  Side-effects and adverse events due to chemotherapy, 
radiotherapy and surgery are prevalent.  While there is some information on toxicity (treatment 
related morbidity: mild toxicity, moderate toxicity, severe toxicity, death due to toxicity) this field is 
non-mandatory and it is not clear if the level of detail collected would suffice to populate a model. 
Assuming the mandatory fields have relatively high completion rates, with the exception of HRQoL, 
disease severity and toxicity, the information currently collected in the existing NCA would provide 
the majority of information required to model the cost-effectiveness of interventions and policies in 
bowel cancer.  As previously noted, there is a dearth of preference-based HRQoL evidence in bowel 
cancer, and the collection of utilities (EQ-5D) within the NCA would be recommended as an 
important and valuable consideration. 
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7.4 Recommendations for bowel cancer  
The evidence base relating to the appropriateness of the EQ-5D in patients with bowel cancer is 
mixed and further validation is required.  All the evidence is in adults and while the NCA inclusion 
definition includes all patients with bowel cancer, the proportion of paediatrics is likely to be 
extremely small and is not considered in this report.  Published evidence which could be used to 
populate the utility values in economic models is extremely poor.  With the exception of information 
on treatment related adverse events/complications, it is thought that the current NCA collects much 
of the information required to conduct economic evaluations.  However, as far as we are aware, 
there does not appear to be a patient questionnaire.  Potential recommendations (PR) and areas for 
future research (FR) are tabulated below (Table 8) with the corresponding narrative provided in 
Appendix F. 
Table 8: Recommendations and associated future research for bowel cancer 
PR.15 Include the EQ-5D in future patient questionnaires alongside a condition specific measure 
such as the EORTC QLQ-C30 and the colorectal module (QLQ-CR29) 
FR.15 Assess the psychometric properties of the EQ-5D using the data collected in the bowel 
cancer audit 
PR.16 Include a severity measure such as Dukes’ staging (to be collected alongside the HRQoL 
data) 
PR.17 Collect mandatory information on adverse events associated with chemotherapy regimens 
(plus radiotherapy adverse events, and surgical complications) 
PR.18 Include additional mandatory fields in the bowel cancer audit 
FR.16 Detailed analyses of fields currently collected in the bowel cancer audit to identify 
recommendations for future mandatory fields 
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8. RESULTS FOR HEAD AND NECK CANCER
8.1 Evidence of appropriateness of EQ-5D in head and neck cancer (WP1.1)
One review was identified which covered all cancers.(31)  No studies for head and neck cancer were 
found by this review.  The searches were conducted in August 2010(31) and an updated search was 
conducted for this project in May 2014. The update searches retrieved 32 citations. None of these 
studies met the inclusion criteria of WP1.1.  While two studies were identified in patients with brain 
cancer, this condition is excluded from the head and neck cancer NCA hence the studies are not 
reviewed here.   As such, there does not appear to be any evidence relating to the appropriateness 
of the EQ-5D in patients with head and neck cancer.  
8.2 Alternative measures in head and neck cancer (WP1.2) 
The evidence identified on alternative measures was extremely limited (Appendix G) and in keeping 
with the recommendations for the bowel cancer audit, it is recommended that the EQ-5D and the 
EORTC QLQ-C30 (plus the QLQ-H&N35 module) are collected in the NCA with a view to assessing the 
psychometric properties of the measures using the NCA data (Table 9). 
Table 9: Summary of evidence on PROMs in head and neck cancer 
Measure 
(N) 
Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change 
over 
time 
Ceiling 
Effect 
EQ-5D (0) NE NE NE NE NE NE No evidence 
EORTC 
QLQ-C30 
EORTC 
QLQ-
H&N35 
The psychometric properties of these measures have not been reviewed in the current report 
N= number of studies used to inform conclusions, KGV: known group validity; NE, no evidence was identified; 
8.3 Evidence for economic evaluations in head and neck cancer (WP1.3) 
Two STAs relating to head and neck cancer were identified from the searches.(57;58)  Both 
examined the clinical and cost-effectiveness of a pharmaceutical intervention plus radiotherapy 
compared to radiotherapy alone in patients with recurrent and/or metastatic head and neck 
cancer,(58) or patients with locally advanced squamous cell carcinoma of the head and neck.(57)  
Both studies quality adjusted survival by assigning mean utility values to the discrete health states.  
Presumably due to the lack of more appropriate evidence, neither study used preference-based 
utility values obtained from patients with head and neck cancer.   
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The head and neck cancer audit does not include a patient questionnaire thus PROMs are not 
currently collected and there does not appear to be an alternative field which could be used to 
predict the required preference-based utility values.  Assuming there is a relatively high completion 
rate, it is thought that this audit collects much of the information required to derive survival curves 
for progression and recurrence of the disease but again key information may be missing such as 
condition severity (measured using information of lesions and required to case-mix when comparing 
providers), current pharmaceutical interventions (type of intervention, concomitant medications, 
remission rates, relapse rates, adverse events) and surgical rates and complications. 
8.4 Recommendations for head and neck cancer 
The searches conducted to identify evidence on the appropriateness of the EQ-5D found no relevant 
studies and published evidence which could be used to populate the utility values in economic 
models is extremely sparse.   While it is likely that with exceptions, the current head and neck cancer 
audit collects much of the evidence needed to perform economic evaluations, this is far from clear.  
In addition, the head and neck audit is completed by clinicians/NHS staff and does not currently 
include a patient completed component.  Potential recommendations (PR) and areas for future 
research (FR) are provided below (Table 10) with the corresponding narrative provided in Appendix 
G. 
Table 10: Recommendations and associated future research for head and neck cancer 
PR.19 Include a patient questionnaire or the provision for electronic collection of PROMs 
PR.20 Include the EQ-5D in future patient questionnaires alongside a condition specific measure 
such as the EORTC QLQ-C30 and the QLQ-H&N35 module 
FR.17 Assess the psychometric properties of the EQ-5D using the data collected in the head and 
neck cancer NCA 
PR.21 Information on adverse events associated with chemotherapy regimens and the side effects 
of surgical interventions and radiotherapy 
PR.22 Collect an appropriate measure of severity, such as mucositis grade alongside information 
on lesions 
PR.23 Include additional mandatory fields in the head and neck cancer audit 
FR.18 Detailed analyses of fields currently collected in the head and neck cancer audit to identify 
recommendations for future mandatory fields 
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9. RESULTS FOR PSYCHOLOGICAL THERAPIES
9.1 Evidence of appropriateness of EQ-5D in psychological therapies (WP1.1)
An existing systematic review provided evidence on the appropriateness of EQ-5D in psychological 
therapies.(59)  A total of 20 studies evaluated the construct validity or responsiveness of the EQ-5D. 
Studies were conducted in a wide range of countries and it is not clear in many if the required UK 
preference weights were used.  (60-80) Mean ages ranged from 39.6 years(78) to 74.1 years.(66)  
Ten studies focused on individuals with depression((60;64;65;67-70;73;78;79), 3 studies focused on 
individuals with anxiety,(71;72;80) and 3 focused on individuals with either depression or 
anxiety.(61;74;75) The remaining 2 studies were surveys of the general population, aiming to 
identify individuals with postnatal depression (63) or depression or anxiety.(76) 
The authors concluded that while the evidence base supports the use of the EQ-5D in patients with 
anxiety and depression, there is evidence to suggest the EQ-5D may lack responsiveness in the 
elderly.(59)  They also noted a stronger correlation with depression scales than anxiety scales in 
patients with anxiety which suggests the known group validity results may be driven by the presence 
of comorbid depression or the depression aspect within anxiety disorders.   The evidence suggests 
the EQ-5D is appropriate in patients with depression, but additional research is required to confirm 
its appropriateness in patients with anxiety conditions (Table 11).  
Table 11: Summary of evidence on EQ-5D for patients receiving psychological therapies 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Adults 
EQ-5D (21) Not reported   Not 
reported  
Good; Good Mixed; not reported 
Authors note that EQ-5D correlations were higher when compared against depression than anxiety 
scales in patients with anxiety (study n=1), that there may be a lack of responsiveness in older 
adults (study n=1) and that the EQ-5D showed greater changes at the lower end of the HRQoL 
spectrum.  
The EQ-5D is appropriate in patients with depression, but additional research is needed to confirm 
its appropriateness in patients with anxiety.  
9.2 Alternative measures in psychological therapies (WP1.2) 
Evidence from WP1.1 for psychological therapies suggests that the EQ-5D is appropriate for use in 
depression and additional research is needed to confirm its appropriateness in patients with anxiety. 
The most relevant evidence for WP1.2 comes from the Oxford PROMS group.(81) This report did 
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not, however, give one single recommendation and did not consider all measures available.  Of most 
relevance to WP1.2 are the report’s considerations about choosing a measure that covers both 
anxiety and depression, for which Clinical Outcomes in Routine Evaluation - Outcome Measure 
(CORE-OM) is preferred over Hospital Anxiety and Depression Scale (HADS), as it has a better level of 
evidence to support it and includes social function. The report states that if a preference measure is 
required, EQ-5D is preferred over the SF-6D.  
For adult populations, the Royal College of Psychiatrists give as examples the patient health 
questionnaire (PHQ-9), a 9-item depression scale intended to diagnose and monitor depression; the 
Generalised Anxiety Disorder Assessment -7 (GAD-7), a seven-item questionnaire used as a 
screening tool and severity measure for generalised anxiety disorder; CORE-OM, used before and 
after therapy. In older adults, the Royal College recommends GAD-7 and HADS, but notes that this 
latter may miss somatic symptoms.  
It is also worth noting that a new measure is in development that is intended to be suitable for use 
across the spectrum of psychotic and non-psychotic mental health conditions. The measure, 
Recovering Quality of Life (ReQoL) is currently under development by the Policy Research Unit in 
Economic Evaluation of Health and Care Interventions (EEPRU) and is due to be available around July 
2015.(82)  Once the measure is available and has been validated in people with depression and 
anxiety, the ReQoL may become a candidate measure for inclusion in the NCA. 
9.3 Evidence for economic evaluations in psychological therapies (WP1.3) 
As no relevant TAs were identified, the most recent clinical guideline (CG) in anxiety and depression 
was reviewed.(83)  The CG encompassed a broad decision space covering pharmacological and 
physical interventions, services (organisation of care, development of staff roles, introduction of 
mental health specialists into primary care), and psychological and psychosocial interventions.  The 
guideline team identified four studies describing economic evaluations for either low-intensity 
(84;85) or high-intensity psychological interventions.(86;87)  The clinical pathway was described 
using discrete health states based on severity of depression using well-established cut-offs relating 
to the Becks Depression Index (BDI).  Mean EQ-5D scores were assigned to the discrete health states 
and the analysts reported the relationship between EQ-5D and severity of depression (measured 
using the BDI mapped onto the CORE-OM) was non-linear. 
30 
The NCA collects information from patients with anxiety or depression receiving psychological 
therapies in the community, and includes a therapist questionnaire and a service user’s 
questionnaire.  The existing models used health states categorised by severity of condition and 
intervention specific relapse rates were used to compare individual therapies.  Responses to the 
type of psychological therapy provided, sub-categorised by high (e.g. cognitive analytic therapy) or 
low (e.g. psycho education) intensity therapy, the number of sessions attended and completion of 
therapy, are mandatory in the retrospective service user questionnaire.  These could potentially be 
used to model adherence and withdrawal rates but it is not clear if there are any fields which could 
be used to model relapse, which is a frequent occurrence in this chronic condition and a key 
parameter for any economic model in this area. 
The retrospective service user questionnaire also includes information on initial and final outcome 
scores such as HADs, CORE-10, and Beck anxiety index (BAI) which would be useful to measure 
severity.  While in theory these could be used to identifying response to treatment, this would 
depend on the timings of the data collection.  There is evidence in the literature which could be used 
to link some of these variables to preference-based utility values (e.g. HADs to EQ-5D).  However, 
the functions currently available have not been validated on external data consequently it is 
recommended that the service user questionnaire also includes a measure which could be used to 
generate utilities. 
9.4 Recommendations for psychological therapies 
The NCA collects information from patients with anxiety or depression receiving psychological 
therapies in the community, and there is a mandatory field which could be used to differentiate 
between the subcomponents of this condition.  The Service user questionnaire includes a measure 
to capture the strength of the therapeutic relationship between clients and their therapists,(88) and 
the retrospective service user questionnaire also includes information on measures such as the 
HADs, CORE-10 and Beck Anxiety Inventory (BAI).  However, there is no measure which could be 
used to generate preference-based scores directly.  Potential recommendations (PR) and areas for 
future research (FR) are provided below (Table 12) with the corresponding narrative provided in 
Appendix H. 
The psychological therapies NCA data is currently being analysed under a separate research project 
(WP3), and the results of this research will inform additional recommendations for the fields in the 
audit (FR.20). 
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Table 12: Recommendations and associated future research for psychological therapies 
PR.24 Collect the EQ-5D in the service user questionnaire alongside clinical measures such as the 
PHQ-9 and HAD-7 
PR.25 Collect the ReQOL in the service user questionnaire once it becomes available 
FR.19 Assess the appropriateness of the EQ-5D and the ReQoL in patients receiving psychological 
therapies using the data from the NCA 
PR.26 All therapists use a common set of measures (to be decided and ultimately synchronised 
with the measure adopted for use in NHS Outcome Framework) 
PR.27 Include additional mandatory fields in the psychological therapies NCA 
FR.20 Detailed analyses of fields currently collected in the NCA is currently being undertaken 
under a separate research project within this programme of work (WP.3).  
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10. RESULTS FOR SCHIZOPHRENIA
10.1 Evidence of appropriatness of EQ-5D in schizophrenia (WP1.1) 
An existing systematic review was updated (89) and a total of 10 studies were included in the new 
updated review. Of the ten included studies, two studies used the UK EQ-5D tariff, one used Finnish 
weights and the remainder were not detailed in Papaioannou et al.(90)  Mean ages ranged from 28.9 
(89) to 41.5 years,(91) and a fairly broad range of psychosis disorders were covered in the studies.  
The majority of measures used to compare and assess the EQ-5D were designed for use in mental 
health conditions, or to capture mental health symptoms.  
The construct evidence (known groups) was good with two studies reporting that the EQ-5D 
detected differences in the expected direction for known groups, characterised by function (GAF), 
severity (PANNS) and condition (ICD).(90;92) However, the evidence for both responsiveness and 
convergent validity was mixed.  For responsiveness, while there was some evidence that the EQ-5D 
was responsive to change, this evidence was limited to the PANSS positive subscale, the Groningen 
social disabilities schedule (GSDS) and the auditory hallucinations rating scale (AHRS), and no 
association was found when changes in the BPRS were small (<25%).  Despite one study reporting 
moderate to large effect size for both symptom and function measures, the relationship between 
the EQ-5D and symptoms (function) was reported as poor in three (three) studies.    In conclusion, 
there is sufficient evidence to raise doubts about the appropriateness of the EQ-5D in patients with 
schizophrenia (Table 13). 
4.2 Evidence of alternative measures in schizophrenia (WP1.2) 
Searches identified three reports of relevance to WP1.2.(93-95)  All three recommended the same 
measures, namely the brief psychiatric rating scale (BPRS) and the positive and negative syndrome 
scale (PNASS). The EMA report states that these are reliable and validated measures, but does not 
provide evidence to support this statement.(95)  The HoNOS and Friends and Family Test are 
recommended as suitable CROM and PREM respectively while the Warwick Edinburgh Mental Well 
Being Scale (WEMWBS) or the short version (s-WEMWBS) is currently recommended and both are 
being tested by the Care Pathways and Packages Project.(96)  As mentioned earlier a new PROM, the 
ReQoL, is currently under development and will be suitable for use across the psychotic (which will 
include anxiety and depression) and non-psychotic (which will include schizophrenia) conditions. 
Once the measure is available and has been validated in people with schizophrenia, the ReQoL may 
become a candidate measure for inclusion in the NCA.    
33 
Table 13: Summary of evidence on measures for schizophrenia 
Condition N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change 
over 
time 
Ceiling 
Effect 
EQ-5D 11 NR NR Good Mixed Mixed NR Not 
appropriate 
HoNOS 
(clinician-
completed) 
The recommendation is based on those in PBR [DH2013] and the psychometric 
properties of this measure have not been reviewed in the current report  
WEMWBS The recommendation is based on those in PBR [DH2013] and the psychometric 
properties of this measure are currently under review elsewhere (96)  
ReQOL This measure is currently in development and will be available in 2015 
N= number of studies used to inform conclusions, KGV: known group validity; NR, the existing review did not 
review this psychometric property. 
10.3 Evidence for economic evaluations in schizophrenia (WP1.3) 
Just one STA relating to schizophrenia was identified.(97)  The evaluation compared pharmacological 
treatments for schizophrenia in adolescents (15-17 years).   As treatment related adverse events 
such as substantial weight gain and somnolence are prevalent, and frequently lead to 
discontinuation of treatment, these were captured within the model framework.  QALYs were 
obtained by assigning mean utility values to the discrete health states and due to lack of more 
suitable data in adolescents, EQ-5D data collected from adults were used.  The results of the 
searches conducted to inform the model parameters suggest the volume of EQ-5D data in patients 
with schizophrenia is very limited and none were available in adolescents.  
The mandatory fields in the schizophrenia NCA do not provide sufficient detail to model the 
individual treatment effects (maintenance, relapse, weight gain etc) as applied in the existing HTA 
cost-effectiveness evaluations in schizophrenia.  Although remission (full or partial) is a mandatory 
field, it is believed these records are subjective clinical decisions.  If this is the case, this evidence 
could be improved through the use of a clinical instrument with clearly defined criteria for remission.  
The rate of patients in remission could then be used to inform economic models comparing 
interventions or providers.  Some of the optional fields in the clinical audit tool, such as the use of 
antipsychotic medications and history of medications in patients not in remission, could supply some 
of the additional evidence required to model the cost-effectiveness of different interventions and 
policies.   There are currently no data collected in the schizophrenia NCA which could be used to 
inform the HRQoL associated with the condition or the interventions prescribed and the inclusion of 
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a variable which could be used to generate preference-based utilities would greatly enhance the 
dataset.   
10.4 Recommendations for schizophrenia 
Based on the evidence reviewed, the EQ-5D is not thought to be appropriate for patients with 
schizophrenia.  It is not believed that there are data in the schizophrenia NCA which could be used to 
inform the HRQoL associated with the condition, either directly through a preference-based 
measure, or indirectly through an alternative measure.  In addition, it is not believed that the other 
variables collected in the audit will suffice to compare providers or conduct robust economic 
evaluations.  Potential recommendations (PR) and areas for future research (FR) are provided below 
(Table 14) with the corresponding narrative provided in Appendix I. 
Table 14: Recommendations and associated future research for schizophrenia 
PR.28 Include both the HoNOS (a clinician-completed measure) and WEMWBS in the 
schizophrenia NCA 
PR.29 Include the ReQOL in the NCA once available and validated in patients with schizophrenia 
FR.21 Assess the psychometric properties of the ReQOL using the data collected in the NCA 
PR.30 Increase the mandatory fields in the NCA to facilitate future economic evaluations 
FR.22 Inspect the fields collected in the NCA with a view to making recommendations on the 
information required to compare providers and conduct economic evaluations 
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11 RESULTS FOR DEMENTIA 
11.1 Evidence of appropriateness of EQ-5D in dementia (WP1.1) 
An existing review which appraised the evidence on the appropriateness of the EQ-5D in dementia 
(n=18) was used.  Although some positive results were reported, in general, there was sufficient 
evidence to raise concerns relating to the appropriateness of EQ-5D in patients with dementia (Table 
15).  A ceiling effect was observed in three studies,(98-100) two studies reported the EQ-5D may not 
be acceptable for patients with severe dementia,(99;101) and two studies reported no relationship 
between self-reported EQ-5D scores and clinical measures.(98;102)  Conversely two of three studies 
reported there was a relationship between proxy scores and clinical variables.(98;103) However, 
several issues with proxy scores were also described. Six studies reported no relationship between 
self-reported and proxy scores (even in patients with mild dementia).(98;100-102;104;105) Patients 
scored higher HRQoL than proxies in those that provided this information and the carers’ responses 
were influenced by the level of dependency of the patient.(100;102;105) In addition, three studies 
reported no association between clinician and carer-proxy scores, with evidence suggesting that 
each may have a more accurate concept of particular attributes of HRQoL.(99;101;106) 
Table 15: Summary of evidence on EQ-5D for dementia 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Self-reported 
EQ-5D (17) Good for 
mild 
dementia. 
Poorer for 
moderate to 
severe 
dementia. 
- Mixed; Poor - Evidence 
of ceiling 
effects 
Proxy-rated 
 EQ-5D  (19) Good - Some positive 
evidence, but 
methods have flaws; 
Fair. 
- Evidence 
of ceiling 
effects 
Concerns about appropriateness. 
11.2 Alternative measures in dementia (WP1.2) 
Searches identified two potentially relevant documents, neither of which makes specific 
recommendations on the selection of instruments to measure HRQoL, despite discussing the 
psychometric properties and appropriateness of different instruments (107;108).     
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In addition to the documents mentioned in the previous paragraph, evidence presented in two 
manuscripts known to the authors is worthy of consideration.(109;110) The use of a bolt-on for 
cognitive impairment has been suggested for EQ-5D,(288) but the proxy-rated EQ-5D+C was found 
to perform similarly to the EQ-5D and its use in isolation is not recommended. (286) The second 
source of evidence, an HTA report on two dementia specific HRQoL instruments, the DEMQOL and 
the DEMQOL-proxy (patient and proxy rated), provides early positive evidence of acceptability, 
validity and responsiveness of these instruments, but requires further validation in datasets 
incorporating a range of clinical indicators and dementia severity levels before they can be 
considered appriate for use in dementia.(287) 
11.3 Evidence for economic evaluations in dementia (WP1.3) 
11.3.1 Cost-effectiveness modelling approach used in recent HTAs in dementia 
One MTA which assessed the clinical and cost-effectiveness of anti-dementia medication 
(acetylcholinesterase inhibitors, i.e. donezepil, galantamine and rivastigmine, and memantine) 
compared to each other and best supportive care for the treatment of Alzheimer’s disease was 
reviewed.(111)  The natural disease history was modelled by two multivariate regression time to 
event models (time to institutionalisation and time to death), which predict events based on age, 
cognition (measured by the Mini-mental State Examination (MMSE)) and functional ability 
(measured by Activities of Daily Living (ADL)). The model quality adjusted survival by assigning mean 
utility values to the discrete health states.  
The TA on Alzheimer’s disease(111) used survival analysis to model mortality and disease 
progression. The audit collects data of in-hospital death, as well as patient’s age which was a 
covariate in the regression models used to predict mortality and time to institutionalisation in the 
economic model. However, the National Audit of Dementia (NAD) does not collect data on the two 
other covariates in both regression models, i.e. measures of cognition and physical ability. There are 
two fields on the casenote audit that provide some information on whether the patient was 
institutionalised before and/or after hospital admission. The only treatment data collected by the 
audit refers to the use of antipsychotic drugs, which are not anticipated to impact on disease 
progression, but may reduce behavioural and psychological symptoms. 
Data collection within the NAD has the objective of allowing comparisons between hospitals in terms 
of standard of treatment and care provided to dementia patients. The focus of the audit is mostly on 
describing the treatment, care and support of these patients. Although this is valuable information, 
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the audit in its current format does not collect any variable that can be used to derive utility 
estimates, directly or indirectly (e.g. through a mapping function). To our best knowledge the 
collection of any PROMs within the NAD is not currently being considered. 
11.4 Recommendations for dementia 
Based on the evidence reviewed, the EQ-5D is not thought to be appropriate for patients with 
dementia.  It is not believed that there are data in the NAD which could be used to inform the 
HRQoL associated with the condition, either directly through a preference-based measure, or 
indirectly through a surrogate.  In addition, it is not believed that the other variables collected in the 
audit will suffice to conduct robust economic evaluations.  PPR and areas for FR are provided below 
(Table 16) with the corresponding narrative provided in Appendix J. 
Table 16: Recommendations and associated future research for dementia 
PR.30 Collect the DEMQOL-U and the DEMQOL-U-proxy in a service user questionnaire alongside 
clinical measures such as the MMSE and ADL. 
FR.23 Assess the appropriateness of the DEMQOL-U and the DEMQOL-U-proxy in dementia 
patients using the data from the NCA 
PR.31 Collect mandatory information on time and date of full-time institutionalisation, type of 
drug therapy administered, death and utility values. 
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12 RESULTS FOR CARDIAC ARRHYTHMIA 
12.1 Evidence of appropriateness of EQ-5D in cardiac arrhytmia (WP1.1) 
Evidence of the appropriateness of the EQ-5D is presented jointly for all cardiovascular disease (CVD) 
conditions considered in the report. This was considered to be an appropriate way to present 
results, given i) the paucity of evidence available for each individual cardiovascular condition, and ii) 
the existence of some overlap of the study populations as defined by the cardiovascular conditions 
(e.g. acute coronary syndrome (ACS)) patients can be treated with coronary angioplasty or cardiac 
surgery, such as coronary artery bypass graft (CABG).  
An existing review was updated,(112) and 12 studies were included in the current review.(113-124) 
The majority of studies applied the EQ-5D UK tariff to estimate utility weights. Five of the studies 
assessed the psychometric properties of the EQ-5D in ACS.(113;115;119;124;125)   Five of the 
studies assessed the psychometric properties of the EQ-5D in heart failure.(116;117;120-122) One of 
the studies examined the acceptability of EQ-5D-5L in cardiac arrhythmia.(123) Four of the studies 
assessed the psychometric properties of the EQ-5D in a patient population that included more than 
one cardiovascular condition in WP1.1. There were three studies that included ACS, coronary 
angioplasty and cardiac surgery, and one study that included coronary angioplasty and cardiac 
surgery.(114)  
Overall, the evidence base assessing the performance of the EQ-5D in cardiovascular conditions is 
mostly positive.  The acceptability of EQ-5D was fair to good in the three studies that assessed this 
property. Evidence regarding reliability was very limited and indicated poor performance.  
Nevertheless, reliability was examined in one study alone and only at health dimension level. 
Construct validity (convergent) between EQ-5D was generally good, and more evident at the index 
than at the health dimension level. This was the psychometric property for which there was more 
robust evidence, given the amount of evidence available and its general concordance. The available 
evidence in terms of construct validity also reinforced that the EQ-5D can distinguish between 
subgroups of patients of varying HRQoL, namely between myocardial infarction (MI) and CABG 
patients.  There was considerable positive evidence of known-group validity across groups defined 
by age, gender and educational level.The ability of EQ-5D to distinguish between groups of different 
disease severity was found to be good. Finally, evidence on responsiveness as change over time was 
poor across the three studies that assessed it, but it should be noted that the methodology used to 
examine itwas not the most adequate. It was concluded that the evidence on responsiveness is 
mostly uncertain, but studies so far suggest that EQ-5D may perform poorly in this characteristic. 
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Importantly, the studies that assessed responsiveness as change over time were all conducted in a 
single disease condition, heart failure, so there is also a question of whether the poor performance 
in this condition is likely to extend to other cardiovascular conditions. One study detected a ceiling 
effect, i.e. a tendency towards single level response, that was considerably more pronounced for 
individual health domains of EQ-5D (especially for self-care), than for the utility score.(114) Evidence 
of ceiling effects for EQ-5D utility scores was also found in a large European study.(125) This may 
translate into less discriminative ability of EQ-5D for patients at lower levels of disease severity.   
Six studies included in the review assessed the psychometric properties of EQ-5D in heart failure, 
and provided evidence of construct (both convergent and known-group) validity, but poor 
responsiveness. For ACS and cardiac surgery there was some evidence of the majority of all reported 
psychometric properties (with the exception of responsiveness), taken from five and four studies 
respectively. EQ-5D performed well in terms of acceptability and validity, but showed poor 
reliability. In the five studies in coronary angioplasty, EQ-5D performed similarly to what was found 
for ACS and cardiac surgery in the same properties. The only evidence found for cardiac arrhythmias 
refered to acceptability of EQ-5D, which was considered good.  Results by cardiovascular condition 
and psychometric property are summarised below in Table 17. 
Table 17: Conclusions on evidence on psychometric properties of EQ-5D in CVD 
Construct Responsiveness 
Condition Acceptability Reliability (KGV;Convergent 
(Ceiling 
effects) 
(Change over 
time) 
Cardiac arrhythmia Good NE NE;NE NE NE 
Heart failure NE NE Good;Good NE Poor 
Coronary angioplasty Fair NE Good;Fair/Good 
Potential 
ceiling 
effects NE 
Adult cardiac surgery Fair/Good Poor Good;Fair/Good 
Potential 
ceiling 
effects NE 
Acute coronary syndrome Good Poor Good;Good 
Potential 
ceiling 
effects NE 
KGV: known group validity; NE: no evidence 
12.2 Routinely collected proxy measures in cardiac arrhythmias (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
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12.3 Evidence for economic evaluations in cardiac arrhythmias (WP1.3) 
Seven economic models from existing TAs were reviewed. Four of the TAs examined the clinical and 
cost-effectiveness of a pharmaceutical intervention in atrial fibrillation (AF),(126-129) while the 
other three assessed devices to manage cardiac arrhythmias.(130-132) Across the TAs, HRQoL in 
patients with cardiac arrhythmias has been assumed to depend mostly on underlying coronary 
disease and its severity, complications subsequent to surgical procedures, symptoms, and adverse 
effects of anticoagulant drugs.(126-132)  Disability following stroke is another important aspect of 
HRQoL, especially in patients at increased risk of stroke, i.e. patients with atrial fibrillation (AF), with 
assigned utility weights varying by level of disability.(126-128) 
Key clinical events in the existing models include death (all cause, cardiovascular and non-
cardiovascular), short and longer term complications from the condition or intervention, and 
hospital readmissions.  The National Audit of Cardiac Rhythm Management (NACRM) already collects 
some of these events, although their collection is not mandatory. Nevertheless, there are other key 
clinical events that would not be captured by this audit, such as readmissions to hospital due to 
clinical deterioration (e.g. hospitalisation due to heart failure worsening).  Furthermore, the NACRM 
only collects data on antiarrhythmic drugs on patients with AF, with no other medication data being 
collected in the two datasets of the audit. These limitations could potentially be overcome by linking 
the NACRM data to datasets, such as some of the other NCA datasets (e.g. heart failure). 
Patient related outcome measures are already collected in the NACRM, the EQ-5D and Atrial 
Fibrillation Effect on Quality Of Life questionnaire, although only for patients undergoing ablation 
procedures. The extension of the collection of PROM data to all patients in the NACRM (preferably 
the EQ-5D), could improve the ability of the audit to inform cost-effectiveness analysis of 
interventions. The value of collecting PROMs data in cardiac arrhythmias may be greater than in 
other conditions where it is possible to map clinical variables to a preference-based measure. In this 
particular case, mapping from clinical variables could be very challenging, given that these variables 
are usually disease specific and there are several underlying cardiovascular diseases that can be the 
cause of cardiac arrhythmias.  
12.4 Recommendations for cardiac arrhythmias 
In summary, no evidence was identified on the validity and responsiveness of the EQ-5D in cardiac 
arrhythmias, although the instrument was considered to have good acceptability (Section 12.1). 
Nevertheless, the validity of EQ-5D has been demonstrated in other related conditions, such as heart 
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failure, as well as more generally in the cardiovascular area. Furthermore, EQ-5D derived utility 
weights have been widely used in cost-effectiveness studies in cardiac arrhythmias, and NACRM 
already collects EQ-5D data in patients with atrial fibrillation who undergo atrial ablation 
procedures. In addition, and although many variables of importance are already collected in the 
audit, there are concerns about the completion rates of fields not included in the NACRM Minimum 
Data Standard and that not all relevant fields to perform robust economic evaluations are collected 
in the audit. The issues and corresponding PR and areas for FR are tabulated below (Table 18) with 
the corresponding narrative provided in Appendix K. 
Table 18: Recommendations and associated future research for cardiac arrhythmias 
PR.32 Extend EQ-5D-5L collection so that it is conducted for both elements of the NACRM, i.e. the 
device and the ablation procedures dataset. implantation of cardiac devices (collected in 
the spreadsheet Device-dataset-5502n-14032014) 
FR.24 Assess the psychometric properties of the EQ-5D-5L in patients with cardiac arrhythmias 
using data collected in the audit 
PR.33 Collect mandatory information on the use of anticoagulant drugs and the occurrence of 
adverse events associated with these drugs, with special attention to bleeding and 
cerebrovascular events 
PR.34 Depending on completion rates of Minimum Data Standard Dataset, consider making these 
fields mandatory 
An erratum has been posted online relating to the collection of the EQ-5D variable in the cardiac arrythmia  audit (http://
bit.ly/1V3aQjC).
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13 RESULTS FOR HEART FAILURE 
13.1 Evidence of appropriateness of EQ-5D in heart failure (WP1.1) 
Six studies included in the updated review in CVD conditions (Section 12.1) assessed the 
psychometric properties of EQ-5D in heart failure, and provided positive evidence of construct (both 
convergent and known-group) validity, but poor responsiveness. Full details on the assessment of 
the appropriateness of EQ-5D in heart failure, and more generally in CVD, are presented in Appendix 
K. 
13.2 Routinely collected proxy measures in heart failure (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
13.3 Evidence for economic evaluations in heart failure (WP1.3) 
Of the three TAs relating to heart failure identified from the searches, two examined the clinical and 
cost-effectiveness of devices to manage cardiac arrhythmia in patients with heart failure.(130;131)  
A third TA examined the clinical and cost-effectiveness of pharmaceutical interventions for the 
treatment of chronic heart failure.(133) The HRQoL estimates applied to health states of the 
economic models in the three TAs were dependent on the severity of heart failure according to the 
New York Heart Association classification (NYHA) and corresponded mostly to EQ-5D utility 
scores.(130;131;133)   
In the existing models, mortality (all cause, cardiovascular and non-cardiovascular) was a key clinical 
event.  The National Heart Failure Audit (NHFA) collects mortality data, but will not allow distinction 
between cardiovascular and non-cardiovascular death, as cause of death is not collected within the 
audit. Furthermore, the NHFA will only provide data on death occurring at the hospital. Other key 
clinical events in the economic models, such as hospitalisation due to heart failure worsening could 
potentially be estimated by using readmission data collected in the audit. Transitions to stable heart 
failure states could also be modelled based on discharge data in the NHFA. Finally, the NHFA data on 
referrals can be used to inform further clinical events, namely cardiothoracic surgery and heart 
transplant, although its collection is not mandatory. 
Importantly, the audit does not provide data on surgical complications and device related 
procedures, which are relevant for those patients requiring a device to manage cardiac arrhythmia 
or heart transplant. The identified gaps in mortality data could potentially be overcome by using 
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external data (e.g. Office of National Statistics). Similarly, data on events related to surgical 
complications and device related procedures could be obtained by linking the NHFA dataset to other 
national audit datasets, namely the Cardiac Rhythm Management datasets.  
Patient related outcome measures are not currently collected in the NHFA.  The inclusion of a 
preference-based HRQoL questionnaire (preferably the EQ-5D), could improve the ability of the 
NHFA to inform cost-effectiveness analysis of interventions. An alternative might be to map from a 
clinical variable currently collected in the NHFA, breathlessness (corresponding to NYHA 
classification for severity), to a preference-based measure, which would be compatible with the 
modelling approaches used in previous TAs. However, the NYHA is only collected at admission and 
readmission, and for mapping purposes it would be valuable to collect this measure at discharge too 
to capture potential benefits of interventions. 
13.4 Recommendations for heart failure 
In summary, the EQ-5D appears to be appropriate in patients with HF, and the current heart failure 
audit collects much of the information required to conduct economic evaluations.  Nevertheless, the 
audit does not collect any HRQoL data, and death rates by cause are not collected. The issues and 
corresponding PR and areas for FR are tabulated below (Table 19) with the corresponding narrative 
provided in Appendix K. 
Table 19: Recommendations and associated future research for heart failure 
PR.35 Collect the EQ-5D (EQ-5D-5L) in the NCA 
FR.25 Assess the responsiveness of the EQ-5D-5L to changes in NYHA (already collected in the 
NCA)using data collected in the audit 
PR.36 Collect mandatory information on cause of death 
FR.26 Analyses of fields currently collected in the heart failure NCA is currently being undertaken 
under a separate research project within this programme of work (WP3) 
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14 RESULTS FOR CORONARY ANGIOPLASTY 
14.1 Evidence of appropriateness of EQ-5D in Coronary Angioplasty (WP1.1) 
Five studies included in the updated review in CVD conditions (Section 12.1) assessed the 
psychometric properties of EQ-5D in coronary angioplasty, and provided positive evidence of 
acceptability, construct (both convergent and known-group) validity, but showed poor reliability. Full 
details on the assessment of the appropriateness of EQ-5D in coronary angioplasty, and more 
generally in cardiovascular disease, are presented in Appendix K. 
14.2 Alternative measures in Coronary Angioplasty (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
14.3 Evidence for economic evaluations in Coronary Angioplasty (WP1.3) 
Five TAs relating to coronary angiography were identified from the searches.(134-138) Three of the 
TAs examined the clinical and cost-effectiveness of pharmaceutical interventions for the treatment 
of a population that included patients who underwent revascularisation (namely percutaneous 
coronary intervention (PCI) and CABG.(134-136)  Another TA examined clinical and cost-
effectiveness of a pharmaceutical intervention, compared to heparin in addition to glycoproteins 
inhibitors for patients with ST elevation myocardial infarction (STEMI) intended for PCI.(137) Finally, 
TA 152 examined the clinical and cost-effectiveness of drug-eluting stents vs. bare metal stents was 
compared in patients with coronary heart disease.(138)  All studies quality adjusted survival by 
assigning mean utility values to the separate health states, the majority of which were derived from 
mean EQ-5D estimates.  In one model utilities were also weighted according to the level of 
subsequent disability in stroke health states.(134) 
The National Audit of Percutaneous Coronary Interventional Procedures (NAPCI) collects data on all 
cause mortality that can be used to model survival in accordance with previous TAs. However, cause 
of death is not collected within the audit, and therefore it is not possible to distinguish between 
cardiovascular and non-cardiovascular mortality. Furthermore, the audit only collects data on death 
occurring at the hospital.  The NAPCI audit collects data on PCI complicationsand revascularisation 
procedures (CABG and PCI) following initial PCI that can be used to inform the occurrence of further 
clinical events within the same hospital episode. There are other fields that also collect data related 
to complications, but these are not part of the minimum standard data. Importantly, the audit does 
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not collect data on all types of stroke or data related to severity of disability following 
cerebrovascular events.  
Limitations on the collection of mortality data could be partially overcome by incorporating external 
data, namely by linkage to mortality registers, or by using estimates from the published literature. 
Linking the PCI audit to other datasets could not only allow the calculation of longer term mortality 
rates, but also the distribution of patients between cardiovascular and non-cardiovascular deaths. 
Even if mortality registers do not allow identifying cause of death, this can be ascertained through 
linkage to other audits or registers (e.g. Hospital Episode Statistics).  A potential alternative approach 
to overcome gaps in mortality data might be to use external evidence on the expected rate of non-
cardiovascular mortality. Clinical events occurring after hospital discharge or not recorded in the 
audit could also be sourced from the published literature or by linking the NAPCI data to other audits 
which collect data related to cardiovascular events (e.g. the Myocardial Ischaemia National Audit 
Project (MINAP) for ACS, and the National Adult Cardiac Surgery Audit (NACSA) for revascularisations 
with CABG).  
The NAPCI does not currently collect patient related outcome measures.  The inclusion of a 
preference-based HRQoL questionnaire (preferably the EQ-5D), could improve the ability of the 
audit to inform cost-effectiveness analysis of interventions. An alternative would be to apply values 
from the published literature to clinical events, as has been done in previous models. However, as 
mentioned before, the audit only collects data on those events that occur during the time spent in 
hospital following the initial PCI. Nevertheless, there is a very important limitation to this approach, 
as it may fail to capture the impact on HRQoL of the interventions, given that it may not be related 
to the occurrence of clinical events alone, but also to any beneficial effect on symptoms (e.g. relief 
of chest pain caused by myocardial ischaemia). Collection of a PROM would have a greater potential 
value to this particular audit, as it would allow HRQoL considerations to be related to events, but 
also to symptomatic differences that may be evident and are not fully accounted for by events. As it 
is, it may be difficult to demonstrate the full symptomatic benefits of intervention over just the 
hospitalisation period following coronary angioplasty, PROM collection should not be limited to this 
period. but also include longer follow-up intervals.  
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14.4 Recommendations for Coronary Angioplasty 
In summary, the EQ-5D appears to be appropriate in patients undergoing coronary angioplasty, and 
the current NAPCI collects some of the information required to conduct economic evaluations. 
Nevertheless, the audit does not collect any HRQoL data, and could be improved by the inclusion of 
more fields and/or making their collection mandatory. The issues and corresponding PR and areas 
for FR are tabulated below (Table 20) with the corresponding narrative provided in Appendix K. 
Table 20: Recommendations and associated future research for coronary angioplasty 
PR.37 Collect the EQ-5D (EQ-5D-5L) in the NCA prior to procedure, after procedure and at least 
one longer follow-up time point 
FR.27 Assess the psychometric properties of the EQ-5D-5L using data collected in the audit 
PR.38 Collect mandatory information on cause of death, type of stroke and severity of disability 
following stroke 
PR.39 Make collection of data on drug therapy, number and type of stents and type of arterial 
access mandatory or at least part of the Minimum Data Standard dataset 
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15 RESULTS FOR CARDIAC SURGERY 
15.1 Evidence of appropriateness of EQ-5D in cardiac surgery (WP1.1) 
Four studies included in the updated review in CVD conditions (Section 12.1) assessed the 
psychometric properties of EQ-5D in cardiac surgery, and provided positive evidence of acceptability, 
construct (both convergent and known-group) validity, but showed poor reliability. Furthermore, 
there was evidence of potential ceiling effects for the EQ-5D in this condition. Full details on the 
assessment of the appropriateness of EQ-5D in cardiac surgery, and more generally in CVD, are 
provided in Appendix K. 
15.2 Routinely collected proxy measures in cardiac surgery (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
15.3 Evidence for economic evaluations in cardiac surgery (WP1.3) 
The searches identified two TAs relating to cardiac surgery. Both TAs examined the clinical and cost-
effectiveness of a pharmaceutical interventions in populations that included  patients managed with 
PCI or CABG,(136) or have an initial coronary angiography for diagnostic purposes, and are then 
allocated to a primary treatment intervention with the majority of patients undergoing PCI.(137) 
None of these TAs assessed cardiac surgery procedures, and only include one type of procedure 
collected in the NACSA, namely CABG. Nevertheless, CABG is the most frequent procedure for which 
data is collected in the NACSA.(139) The two TAs quality adjusted survival by assigning mean EQ-5D 
utility values to the separate health states. 
Similarly to other CVD audits, the data collected in the NACSA allows modelling all cause mortality, 
but does not allow distinguishing between cardiovascular and non-cardiovascular mortality. 
Furthermore, the collection of in-hospital death alone can limit the use of the audit to inform cost-
effectiveness analysis. The NACSA also collects data that will inform the occurrence of several 
complications and further clinical events following initial surgery, although this is limited to the 
period of hospitalisation. Limitations on the collection of mortality data could be partially overcome 
by incorporating external data, namely by linkage to mortality registers, or by using estimates from 
the published literature. Linking the NACSA to other datasets could not only allow the determination 
of longer term mortality rates, but also the distribution of patients between cardiovascular and non-
cardiovascular deaths. Even if mortality registers do not allow the identification of the cause of 
death, this can be ascertained through linkage to other audits or registers (e.g. Hospital Episode 
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Statistics), as described for coronary angioplasty in Section 14.3. Clinical events occurring after 
hospital discharge or not recorded in the audit could also be sourced from the published literature 
or by linking this NACSA to other CVD related audits. The considerations in this section apply mostly 
to CABG. Linkages to other audits and registers may be of relevance for less frequent cardiac surgery 
procedures, namely valve repair/replacement, aortic procedures and heart transplant, but 
identifying them would require further exploration of the clinical pathways following these 
procedures. 
 
The NACSA audit does not currently collect patient related outcome measures.  The inclusion of a 
preference-based HRQoL questionnaire (preferably the EQ-5D), could improve the ability of the 
audit to inform cost-effectiveness analysis of interventions. Similarly to the coronary angioplasty 
case, an alternative would be to apply values from the published literature to clinical events, as has 
been done in previous models. However, the audit does not collect all relevant clinical events, such 
as further ACS, and only collects data on those events that occur during the time spent in hospital 
following the initial PCI. As for coronary angioplasty, this approach may fail to capture the full impact 
on HRQoL attributable to the interventions, as HRQoL may not be related to the occurrence of 
clinical events alone, or to any beneficial effect on symptoms. 
 
Although NYHA and Canadian Cardiovascular Society classification scores are collected in the NACSA, 
which capture some of the symptomatic dimension and can potentially be mapped into HRQoL 
measures, the collection is limited to stable patients in the pre-operative stage, and therefore not 
very useful in this context. The collection of a PROM would allow HRQoL considerations to be related 
to events, but also to symptomatic differences. As it is, it may be difficult to demonstrate the full 
symptomatic benefits of an intervention over just the hospitalisation period following cardiac 
surgery, PROM collection should not be limited to this period, but should also include longer follow-
up intervals. 
 
 
15.4 Recommendations for cardiac surgery 
In summary, the EQ-5D appears to be appropriate in patients undergoing cardiac surgery, and the 
current NACSA collects some of the information required to conduct economic evaluations.  
Nevertheless, the audit does not collect any HRQoL data, and could be improved by including more 
fields and/or making some existing fields collection mandatory. The issues and corresponding PR and 
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areas for FR are tabulated below (Table 21) with the corresponding narrative provided in Appendix 
K. 
 
Table 21: Recommendations and associated future research for cardiac surgery 
PR.40 Collect the EQ-5D (EQ-5D-5L) in the NCA prior to procedure, after procedure and at least at 
one longer follow-up time point. 
FR.28 Assess the psychometric properties of the EQ-5D-5L using data collected in the audit 
PR.41 Collect mandatory information on cause of death, type of stroke, severity of disability 
following stroke, and ACS and PCI on follow-up. 
PR.42 Depending on completion rates of completeness assessment dataset, consider making 
these fields mandatory 
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16 RESULTS FOR ACUTE CORONARY SYNDROME 
16.1 Evidence of appropriateness of EQ-5D in acute coronary syndrome (WP1.1) 
Five studies included in the updated review in CVD conditions (Section 12.1) assessed the 
psychometric properties of EQ-5D in acute coronary syndromes, and provided positive evidence of 
acceptability and construct (both convergent and known-group) validity, but showed poor reliability. 
Full details on the assessment of the appropriateness of EQ-5D in acute coronary syndrome, and 
more generally in CVD, are provided in Appendix K. 
16.2 Alternative measures in acute coronary syndrome (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
16.3 Evidence for economic evaluations in acute coronary syndrome (WP1.3) 
Five TAs relating to ACS were identified from the searches.(134-137;140)  Four of the TAs examined 
the clinical and cost-effectiveness of paharmaceutical interventions for the treatment of people who 
have suffered an ACS.(134-137)  Another TA examined the clinical and cost-effectiveness of statins 
for the prevention of coronary heart disease (including ACS).(140)  All studies quality adjusted 
survival by assigning mean utility values to the separate health states, the majority of these values 
having been obtained via EQ-5D. One model weighted utilities according to levels of disability in the 
stroke health states. (134) 
The data collected in MINAP could be used to model the different types of mortality (all cause, 
cardiovascular, and non-cardiovascular), but will only provide data on death occurring at the 
hospital. The MINAP also collects data on complications following ACS (bleeding, reinfarction), as 
well as reperfusion procedures (for STEMI patients) that can be used to inform the occurrence of 
further clinical events within the same hospital episode. Moreover, the audit does not provide data 
on the occurrence of stroke related events, and the level of disability resulting from these. Limitation 
on the collection of mortality data, could potentially be overcome by incorportating external 
published data or by linkage to other datasets (mortality registers, Hospital Episode Statistics, other 
audits) or longitudinal linkage across multiple MINAP entries (for further hospitalisations due to 
ACS). Another alternative is to use risk scores, such as the Global Registry of Acute Cardiac Events, to 
estimate cardiovascular mortality, as well as the risk of future MI events, in hospital and at 6 
months.(141)  Another limitation of the MINAP to inform cost-effectiveness studies, is that it 
provides incomplete coverage of other relevant clinical events that may occur during the initial 
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episode. This limitation could potentially be addressed by linking data to other audits, such as the 
NAPCI.  
The MINAP does not currently collect patient-reported outcome measures.  The inclusion of a 
preference-based HRQoL questionnaire (preferably the EQ-5D), could improve the ability of the 
audit to inform cost-effectiveness analysis of interventions. An alternative would be to apply values 
from the published literature to clinical events, as has been done in previous models. However, as it 
has been highlighted before, the MINAP does not collect all relevant data regarding clinical events, 
namely the occurrence of ischaemic and haemorrhagic strokes and level of disability following 
stroke. Even if the audit collected all relevant clinical events, applying utility weights to the clinical 
events alone may fail to capture the impact on HRQoL of the interventions if this extends beyond 
changing the frequency of the events and has an effect on symptoms too.   Similarly to the PCI audit, 
collection of a PROM would allow HRQoL considerations to be related to events, but also to 
symptomatic differences that may be evident and are not fully accounted for by events. The issue 
regarding duration of follow-up period for the collection of PROMs in the NAPCI also applies here, as 
it may be difficult to demonstrate the full symptomatic benefits of interventions over just the 
hospitalisation period following ACS. Therefore, the collection of PROMs beyond the initial 
hospitalisation episode would be useful to ensure that any longer term symptomatic impact of 
treatments is captured. 
16.4 Recommendations for acute coronary syndrome 
In summary, the EQ-5D appears to be appropriate in ACS patients, and the current MINAP collects 
some of the information required to conduct economic evaluations.  Nevertheless, the audit does 
not collect any HRQoL data, and could be improved by including more fields and/or making their 
collection mandatory. The issues and corresponding PR and areas for FR are tabulated below (Table 
22) with the corresponding narrative provided in Appendix K.
Table 22: Recommendations and associated future research for acute coronary syndrome 
PR.43 Collect the EQ-5D (EQ-5D-5L) in the NCA at admission and at least one longer-term follow-
up time point.  
FR.29 Assess the psychometric properties of the EQ-5D-5L using data collected in the audit 
PR.44 Collect mandatory information on occurrence and type of stroke, severity of disability 
following stroke. 
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17. AGE AND COMORBIDITIES
The evidence available on age was extracted as reported in the reviews, or from the primary studies 
(in the case of the reanalysis, updates and the new review).  With the exception of dementia (mean 
age range 61-81 years) and diabetes (mean age range 55-67 years), the subjects included in the 
primary studies covered a very broad range across all the conditions.  With the exception of the 
mental health condition, no reference was made to the possibility of the EQ-5D being less 
responsive in older age groups.  Consequently it is assumed that the results and conclusions drawn 
will generalise across a large age spectrum. 
The presence of comorbidities in subjects was not available from either the reviews or from most of 
the primary studies reviewed, thus the reported exclusion criteria were used as an indicator of the 
possible presence of comorbidities.  For example if the presence of comorbidities was not identified 
as an explicit exclusion criteria in the primary study, it was assumed that subjects with comorbidities 
were included in the primary studies.  The only exclusion criteria identified which related to the 
presence of comorbidities were: additional specific mental health related conditions such as the 
presence of schizophrenia (in the published metal health review and in the diabetes 
studies),[Peasgood; Janssen] or the history and severity of cardiovascular conditions (in the updated 
cardiovascular review).  Based on the absence of broader comorbidity related exclusion criteria, the 
broad age ranges covered, and the fact that the prevalence of comorbidities rises steeply by age, it is 
assumed that the results and conclusions drawn will generalise across subjects with comorbidities. 
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18. SUMMARY 
The following section provides an overview of the results presented within the individual sections of 
the report.  A summary of the evidence used to inform the conclusions for WP1.1 and WP1.2 is 
provided in Table 23 and 24.  The report concludes with recommendations and suggested areas for 
future research.  This section provides an overview only and it is recommended that the preceding 
sections and the corresponding Appendices are used for details on particular conditions. 
 
18.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
IBD: A review of primary studies (n=2) provides evidence of acceptability, reliability, and known 
group/convergent validity for the EQ-5D in adults with IBD.  However the evidence on the 
responsiveness of the EQ-5D is mixed with some ceiling effects and potential insensitivity to changes 
over time reported.  While the EQ-5D is considered to be acceptable, additional validation is 
required particularly in patients with severe IBD and those undergoing surgical procedures.  A review 
of evidence of PROMs for paediatrics provides evidence of acceptability, reliability and known 
group/convergent validity for the PedsQLTM (5 studies) in paediatrics with IBD.  The PedsQLTM does 
not currently have an associated preference-base tariff, but it has both self-report and parent/carer 
versions and covers the full age spectrum for paediatrics (2-18 years).  Additional preference-based 
measures are also recommended for use in paediatrics with IBD. 
Epilepsy: A review of evidence of PROMs provides evidence of reliability and known group validity 
for the PedsQLTM (5 studies) in paediatrics with epilepsy, but the strength of the evidence supporting 
sensitivity to changes over time was less evident.  While considered to be acceptable, additional 
validation is required to support the long term use of the PedsQLTM in this population.  As with IBD, 
additional paediatric preference-based measures are recommended for use in paediatrics with 
epilepsy. 
Diabetes: A reanalysis of an existing review (n=16 primary studies) provided evidence that the 
acceptability and reliability of the EQ-5D are good. There was some evidence of ceiling effects which 
may affect responsiveness in newly diagnosed diabetics and those without complications. Construct 
validity was generally good when compared to diabetes specific and generic quality of life measures, 
with a few exceptions, most notably in vision. Problems with the EQ-5D in vision have been noted 
elsewhere and addressed through the production of a vision “bolt-on” for the EQ-5D. It is 
recommended this is used alongside the EQ-5D. Paediatric measures were not reviewed due to time 
constraints and a low prevalence of diabetes in this population.  
Bowel cancer: A reanalysis and update of an existing review (n=9 primary studies) provided mixed 
evidence regarding the construct validity and responsiveness of the EQ-5D. Acceptability, reliability 
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and ceiling effects were not reported by the original review authors. In some cases, known group 
validity appeared good against both cancer specific and generic measures, whilst in others it was 
unable to detect differences between groups where condition specific measures (EORTC QLQ-C30 or 
QLQ-CR38) could. One study reported convergent validity of the EQ-5D against TNM stages was low, 
as was the case for several other cancer specific and psychological symptom specific measures or 
subscales. However, some measures and subscales had moderate correlations. Responsiveness was 
also mixed, with the EQ-5D able to detect a change in health status over time in some cases, but not 
in others, where condition specific or symptom specific measures and subscales such as the HADS 
depression score, FACTC and EORTC measures did. It was concluded that the EQ-5D could not be 
recommended without further validation. A review of all alternative measures that could be used 
was not conducted, but it is recommended that the EQ-5D be used in conjunction with the EORTC-
C30, which has a UK utility tariff, and the colorectal module EORTC QLQ-CR29 . 
Head and neck cancer: One review was identified and an update search conducted. No primary 
research studies relating to the psychometric properties of the EQ-5D in head and neck cancer were 
identified. Searches identified seven published clinical or research guidelines relating to other 
measures, but none of these were based on up to date evidence. Given the limited evidence 
available, it is recommended that the EQ-5D is used alongside the EORTC QLQ-C30 and head and 
neck specific module, the QLQ-H&N35, in keeping with the recommendations for bowel cancer. 
Psychological therapies: An existing review provided evidence from 20 primary studies relating to 
the EQ-5D in psychological therapies. Construct validity (both known group and convergent) was 
reported to be good, though data from one study showed that the EQ-5D correlated better with 
depression-specific measures and subscales than with anxiety-specific ones in people with anxiety. 
This suggests that additional research is required to confirm the appropriateness of the EQ-5D in 
patients with anxiety. Responsiveness was more mixed, but generally good, though notably one 
study in the elderly showed poor responsiveness. Better responsiveness of the EQ-5D was observed 
at the lower end of the HRQoL spectrum (e.g. severe depression) when compared to the SF-6D, 
which was more sensitive to changes at the top end of the spectrum. Overall, the EQ-5D was 
considered appropriate for use in anxiety and depression, though further validation work is required 
in anxiety. Searches were conducted to identify other measures. In keeping with The Royal College 
of Psychiatry, the GAD-7 and PHQ-9 measures are recommended for use alongside the EQ-5D. 
ReQoL, a measure currently in development by EEPRU for use in psychotic and non-psychotic mental 
health conditions is due to be available in July 2015, and could be considered for use once available.  
Schizophrenia: An existing review was updated. A total of ten primary research studies were 
identified. Evidence was mixed. Construct validity by known group (defined by severity, diagnosis 
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subgroup and function) was good, but both construct validity by convergent methods and 
responsiveness by change over time were mixed. The EQ-5D was responsive to change over time in 
two studies, but the correlations between change scores in another study were only significant 
between the EQ-5D and an affect subscale (PANSS positive subscale), a social function scale (GSDS) 
and an auditory hallucination scale (AHRS). Small changes were not reflected in the EQ-5D scores. 
There are sufficient concerns with the EQ-5D in this population to prevent its recommendation. 
Three guidelines relating to other measures were identified and all recommended using the BPRS 
and the PANSS. Within the recently introduced payment by results initiative, the patient-reported 
measures used are WEMWBS and s-WEMWBS, and a clinician-reported measure, HoNOS, is also 
used. It is recommended that the same measures are used for the NCA. In this population, it may be 
useful to include a clinician-reported measure alongside patient-reported measures. ReQoL, could 
be considered as an alternative once available. 
Dementia: An existing review provided evidence that there are some concerns relating to the use of 
the EQ-5D in dementia, including ceiling effects, and a lack of relationship between self-report and 
clinical measures. This review focussed some attention on the convergent validity between self-
report and proxy-report, showing there was no relationship between self and proxy reports even in 
mild disease, and no association between carer-proxy and clinician scores, perhaps due to each 
having better insight in different attributes. Other measures were considered in two guidelines, and 
two reports known to the authors. It is recommended that two dementia-specific preference-based 
measures, the DEMQOL-U and the DEMQOL-U-proxy, should be collected in the audit alongside 
cognition and functional ability measures (see summary for WP1.3) 
Cardiovascular conditions:  An existing review (2010)(112) updated and a total of 12 primary studies 
were included in the update.  As there was substantial overlap between the study populations, and a 
very limited amount of evidence for some of the individual CVD conditions the evidence is 
summarised collectively.  Overall, the review provides evidence that the EQ-5D is adequate in CVD, 
being acceptable in the majority of studies and having good construct validity (known group and 
convergent).  There was some evidence of ceiling effects (although this is unlikely to be observed in 
the hospitalised patients within the CVD audits), and there was very little evidence on its reliability.  
Additional evidence was required on its sensitivity to detecting small changes in HRQoL over time. 
 
In summary, evidence from four new systematic reviews of primary studies (IBD adults, IBD 
paediatrics, epilepsy paediatrics, bowel cancer), four updates of existing systematic reviews 
(epilepsy adults, diabetes, bowel cancer, CVD) and two existing systematic reviews (psychological 
therpay) were used to identify if the EQ-5D was appropriate in the 13 health conditions.  No 
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evidence was found for head and neck cancer.  Six reviews of the literature, augmented with 
literature known to the authors were used to identify alternative or additional PROMs for patients 
with epilepsy (paediatrics), IBD (paediatrics), schizophrenia, cancer, dementia, patients receiving 
psychological therapies. 
The psychometric properties of the EQ-5D were found to be adequate in ten of the 13 conditions. 
The exceptions were epilepsy (where the PedsQLTM was recommended), schizophrenia (where 
WEMWBS, to be replaced by ReQOL was recommended) and dementia (where DEMQOL-U was 
recommended).  While the EQ-5D has been shown to be appropriate in the majority of the 13 
conditions, the literature used to inform these conclusions was limited for several conditions and 
there was evidence of a potential ceiling effect or insensitivity to small changes in HRQoL.   
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Table 23: Summary of evidence supporting the psychometric properties of EQ-5D in all conditions 
Condition N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change  
over time 
Ceiling  
Effect 
IBD 2 Good Good Good Good Mixed Mixed Acceptable but not appropriate 
for paediatrics 
Epilepsy  5 NE NE Good Good Mixed Poor All evidence in adults. Not 
appropriate for paediatrics 
Diabetes  16 Good Good Good Mixed Good Poor Acceptable* 
Bowel Cancer 9 NR  NR Mixed Poor Mixed NR Acceptable 
Head and Neck Cancer 0 NE NE NE NE NE NE No evidence 
Psychological therapies  21 NR NR Good Good Mixed NR Acceptable 
Schizophrenia 11 NR NR Good Mixed Mixed NR Not appropriate 
Dementia 21 Mixed NR Mixed Poor NR Poor Not appropriate 
Cardiac arrhythmia 1 Good NE NE NE NE NE Acceptable 
Heart failure 6 NE NE Good Good  Poor NE Acceptable 
Coronary angioplasty 5 Fair NE Good Fair/good NE Poor Acceptable 
Cardiac surgery 4 Fair/good Poor Good  Fair/good NE Poor Acceptable 
Acute coronary 
syndrome 
5 Good Poor Good  ~Good NE Poor Acceptable 
N= number of studies used to inform conclusions, KGV: known group validity; *Not appropriate for DM related vision problems, or neuropathy; NE, no evidence was 
identified; NR, the existing review did not review this psychometric property;  
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Table 24: Recommended measure when the EQ-5D is not appropriate  
Condition Alternative measure N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change  
over time 
Ceiling  
Effect 
IBD paediatrics
a 
PedsQL 5 Good Good Good No evidence No 
evidence 
No 
evidence 
Acceptable 
 PedsQL GI module This measure is currently being validated and will be available shortly 
Epilepsy 
paediatrics 
PedsQL 5 No evidence Good Good No evidence Unclear No 
evidence 
Acceptable 
 PedsQL epilepsy module This measure is currently in development and it is unclear when it will be available 
Diabetes (daily 
management) 
DHP  The recommendation is based on those in PBR [DH2013] and the psychometric properties of 
this measure have not been reviewed in the current report 
Diabetes (vision) EQ-5D vision bolt on  This measure requires additional validation in a large dataset 
Bowel Cancer EORTC QLQ-C30 
EORTC QLQ-CR38/29 
 The psychometric properties of these measures have not been reviewed in the current report 
Head and Neck 
Cancer 
EORTC QLQ-C30 
EORTC QLQ-H&N35 
 The psychometric properties of these measures have not been reviewed in the current report 
Psychological 
therapies  
PHQ-9  Recommended by the Royal College of Psychiatrists 
GAD-7  Recommended by the Royal College of Psychiatrists 
ReQOL  This measure is currently in development and will be available in 2015 
Schizophrenia HoNOS (clinician-
completed) 
 The recommendation is based on those in PBR [DH2013] and the psychometric properties of 
this measure have not been reviewed in the current report  
WEMWBS  The recommendation is based on those in PBR [DH2013] and the psychometric properties of 
this measure are currently under review elsewhere [DH3013] 
ReQOL  This measure is currently in development and will be available in 2015 
Dementia DEMQoL-U 
 
 These measures (patient and proxy rated) provided early positive evidence of acceptability, 
validity and responsiveness, but requires further validation in datasets incorporating a range of 
clinical indicators and dementia severity levels. 
N= number of studies used to inform conclusions, KGV: known group validity;  
a 
consider the PedsQL GI module as an adjunct to the core measure 
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18.2 Summary of evidence required for use in economic evaluations (WP1.3) 
 
IBD: The EQ-5D is currently collected in the audit, but as it is not collected at the same time as other 
key variables used in the economics (for example, surgery or flares in symptoms), its usefulness in 
comparing interventions is limited.  It may be possible to use a clinical variable (for example the 
Crohn’s disease activity index (CDAI) in patients with CD) and an existing relationship between the 
CDAI and EQ-5D to enable the NCA data to be used in economic evaluations.  Despite the issue with 
the timing of collections, the EQ-5D would be useful when comparing providers and if the timings of 
data collection could be synchronised with the clinical data, then it could be used in standard 
economic evaluations.  While the audit collects much of the information required to conduct 
economic evaluations, for example the aggregate numbers of surgeries and surgical complications 
could be used to compare providers, it is not clear if there is sufficient evidence to adjust for case-
mix.  There are also areas where additional evidence, if mandatory, would be beneficial for future 
economic evaluations.  These include details of pharmaceutical interventions and associated 
response and relapse data collected at the same time as a clinical variable such as the Crohn’s 
disease activity index, surgical rates including type of intervention, success rate and associated 
complications. 
Epilepsy: The existing patient questionnaire collects PREMs rather than PROMs and there is no 
existing variable within the current audit which could be used to map to a preference-based 
measure for use in economic evaluations.  While the PREMs could be used to compare providers, 
their use in economic evaluations is limited.  The review of existing economic evaluations identified 
that there was no suitable preference-based evidence in the literature for paediatrics with epilepsy.  
It is thought that the current audit contains insufficient detailed evidence on seizure frequency and 
severity, pharmaceutical interventions (and associated response, withdrawal rates and adverse 
events), surgical interventions and death rates to conduct formal economic evaluations with these 
data. 
Diabetes: The existing audit does not include a patient questionnaire.  A PREM focussed 
questionnaire for patients receiving secondary care is currently being piloted, although this is not 
believed to cover patients treated in primary care.  The evidence collected in this questionnaire will 
be useful when comparing providers.  There is a relatively large evidence base on preference-based 
data in patients with diabetes which could be used to inform formal economic models.  However, 
there are gaps in this evidence where data collected in the audit would be beneficial.  In particular, 
for patients with diabetes related vision conditions and to capture the HRQoL associated with 
hypoglycaemic events.   The audit collects much of the evidence required to conduct formal 
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economic evaluations and if the inpatient data could be linked to GP records this would expand the 
evidence available considerably.  There would remain some issues relating to the timing of the data 
collection, but it is believed that these data could be used to inform formal economic evaluations.   
Bowel cancer: The bowel cancer audit does not include a patient questionnaire thus PROMs are not 
currently collected and existing literature on preference-based data which could be used to inform 
formal economic evaluations is sparse.  The audit collects some of the information required to 
compare providers and economic evaluations such as survival, progression and staging of disease 
(Dukes’ stage).  However, key variables such as toxicity due to chemotherapy and adverse effects of 
surgery and radiotherapy are not currently mandatory fields.   
Head and neck cancer: The head and neck cancer audit does not include a patient questionnaire 
thus PROMs are not currently collected and there does not appear to be an alternative field which 
could be used to predict the required preference-based utility values.  Assuming there is a relatively 
high completion rate, it is though that this audit collects much of the information required to derive 
survival curves for progression and recurrence of the disease but again key information may be 
missing such as condition severity (measured using information of lesions and required to case-mix 
when comparing providers), current pharmaceutical interventions (type of intervention, 
concomitant medications, remission rates, relapse rates, adverse events) and surgical rates and 
complications. 
Psychological therapies: Although the audit for patients receiving psychological therapies does not 
collect PROMs, there is a service user questionnaire which could potentially be amended to include a 
PROM.  Two measures (the Beck’s depression index, and the Beck’s anxiety index) are also collected 
in the audit and it is possible that this evidence could be used to predict preference-based utility 
data using existing published relationships.  There also appears to be an ‘outcome measure’ within 
the retrospective audit but it is unclear what this measure is hence it is not possible to determine its 
usefulness.  Relapse rates are high for this condition and compliance to therapy can be problematic.  
Together with severity of the condition, these are key variables within economic evaluations but it is 
not clear if there are currently any mandatory fields within the audit relating to these.  This audit is 
currently being used as a case-study in an associated project (WP3), and the results of this project 
will provide an indication of what can be achieved with the data collected. 
Schizophrenia: Although the audit includes a service user and carer questionnaire, these do not 
currently include a PROM, concentrating of experience of and satisfaction with the health services 
provided.  These data will be useful when comparing providers, but cannot be used to inform 
economic evaluations.  It is not believed that the mandatory fields in this audit provide sufficient 
detail to model individual treatment effects (maintenance, relapse, compliance, weight gain etc), but 
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some of the optional fields could provide some evidence on antipsychotic medications and history of 
medications in patients not in remission.  While there is a mandatory field relating to ‘relapse’ it is 
believed this is a subjective clinical decision, thus it may not be possible to use this in economic 
models. 
Dementia: In its latest round, the dementia audit does not include a service user or carer 
questionnaire and thus no PROMs are currently collected.  The information collected in the audit 
would enable comparison of providers (i.e. hospitals) in terms of the standard of treatment and care 
provided to patients with dementia, and to compare the performance of the individual hospital over 
time.  However, it is not clear if the data could be case-mixed using variables such as cognition and 
physical ability.  In addition to evidence on HRQoL, to conduct formal economic evaluations, the 
audit would require additional detailed mandatory information such as dementia diagnosis, MMSE 
score, ADL score, type of pharmaceutical therapy administered and death rates. 
Cardiac arrhythmia: The NACRM currently collects the EQ-5D and the condition-specific AFTEC in a 
patient questionnaire administered pre and post (6 month and 12 month) the ablation procedure.  
However, only patients undergoing ablation procedures complete the questionnaire and if this could 
be extended to all patients within the audit, this would increase the scope of the audit data in 
relation to performing economic evaluations and comparing providers.  Although there is currently 
insufficient information in the mandatory fields to conduct formal economic evaluations, the data 
standard subset has additional information that could be used, subject to completion levels.  In 
particular, the following information would ideally be required for informing economic models: 
normal sinus rhythm, permanent AF with uncontrolled symptoms, permanent AF with controlled 
symptoms, and death rates, type of intervention (CRT pacemaker, CRT defibrillator, dual-chamber or 
single chamber pace-makers, implantable cardioverter defibrillators) and associated 
success/complication rates, cardiac resynchronisation therapy, anti-coagulant drugs and 
thromboembolic, ischaemic and bleeding events. 
Heart Failure: Although no PROMs are currently collected in the NHFA, it may be possible to utilise 
the NYHA breathless severity data to obtain proxy preference-based utility scores to generate QALYs 
in economic evaluations.  However, the NHFA data are only collected on admission and re-
admission.  To inform the benefits of interventions, they would also need to be collected post 
intervention and on discharge from hospital.  In addition, the collection of EQ-5D-5L directly within 
the audit would capture the benefits of interventions and procedures directly thus reduce the 
uncertainty inherent within mapping functions.  Excluding HRQoL information, the current NHFA 
collects much of the information required to conduct formal economic evaluations and to compare 
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providers, and it is possible that the gaps identified (mortality and surgical complications) may be 
available in external datasets if these could be linked in some way.   
Coronary angioplasty: Although the NAPCI does not collect PROMs, due to the discrete nature of the 
health states in the typical clinical pathway, it would be possible to utilise evidence in the literature 
to populate HRQoL values in economic evaluations.  However, the inclusion of a PROM (preferably 
the EQ-5D-5L) within the audit would enable direct comparison of providers and interventions using 
the audit data.  In addition, depending on the timing of collection, EQ-5D-5L collected via the audit, 
could provide useful information on the longer-term effects (for example 6 month and 12 month 
post discharge) on HRQoL associated with reductions in symptoms, rather than the immediate direct 
effect of specific interventions and procedures (i.e. during hospitalisation).  Excluding HRQoL 
information, the NAPCI does collect much of the information required to conduct formal economic 
evaluations and to compare providers.  Again it may be possible to use external datasets to 
supplement gaps in the evidence collected (e.g. mortality and surgical complication rates) for 
economic evaluations, but this would not be particularly informative when comparing providers. 
Cardiac surgery: The NACSA audit does not collect PROMs, and as discussed for the NAPCI, while it 
may be possible to utilise evidence from the literature when conducting economic evaluations of 
interventions, this form of information is not particularly informative when comparing providers and 
it is recommended that the EQ-5D-5L is collected within the audit with follow-up data to capture the 
longer-term HRQoL benefits of interventions.  Excluding the HRQoL information, the information 
collected within the audit would suffice to compare providers and would provide a substantial 
amount of the evidence required to conduct formal economic evaluations of interventions 
(assuming a relatively high completion rate for all fields).  The exceptions are again the mortality 
information, surgical complications and longer term information on subsequent events.  The latter 
may be available from external datasets if these could be linked in some way. 
Acute coronary syndrome: The MINAP does not collect PROMs and as discussed for the PCI audit, 
while it may be possible to utilise evidence from the literature when conducting economic 
evaluations of interventions, this form of information is not particularly informative when comparing 
providers and it is recommended that the EQ-5D-5L is collected within the audit with follow-up data 
to capture the longer-term HRQoL benefits of interventions.  Excluding the HRQoL information, the 
information collected within the audit would provide a considerable amount of the information 
required to model the cost-effectiveness of interventions and policies in ACS assuming relatively 
high completion levels.   
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In summary, while the evidence collected in the individual audits will allow comparison of providers 
in many cases, it is clear that the mandatory fields in most of the audits will not provide sufficient 
detailed information to perform formal economic evaluations.  The main omission is the lack of 
PROMs which limits the flexibility of the data in terms of comparing either providers or interventions 
used in routing clinical practice.  However, many of the audits contain optional fields which would be 
useful for economic evaluations and enforcing the collection of key variables is recommended in 
many of the audits.  A recurrent issue relates to the level of detail collected and the timing of the 
variables collected.  To be useful for economic evaluations, many of the variables used have to be 
synchronised in terms of timing of collection, and many need to be collected over periods of time to 
assess progression or relapse etc.  An additional key issue which arises throughout many of the 
reviews is the collection of information relating to side effects of pharmaceutical interventions and 
adverse events associated with surgical procedures and radiotherapy.  The audits could provide 
valuable information on these rates, and the effects they have on patients’ HRQoL, when used and 
performed in routine clinical practice.  
 
18.3 Summary of recommendations and associated areas for future research  
The reviews undertaken in this project have produced a relatively large number of condition specific 
and generic recommendations.  Many of the recommendations would require additional supporting 
research and the majority of the research could be conducted in due course using the data collected 
in the corresponding NCAs.  The recommendations and areas for future research relate to the 
development of patient questionnaires in the NCAs that do not currently collect information from 
service users and minimum mandatory fields required to perform economic evaluations using the 
NCA data. 
 
Patient questionnaires: The majority of the NCAs do not currently include a patient questionnaire 
(bowel cancer, head and neck cancer, dementia, heart failure, coronary angioplasty, cardiac surgery, 
acute coronary syndrome).  While it is possible to source the HRQoL evidence required  to inform 
preference-based utility values in economic evaluations from the literature for some of the 
conditions, it is recommended that priority is given to developing patient questionnaires for the 
bowel cancer and head and neck cancer audits, as the evidence in the literature in these conditions 
is very sparse.  It is also recommended that the patient questionnaire used in the diabetes secondary 
care audit is adapted and modified for use in the diabetes primary care audits to collect HRQoL 
evidence relating to hypoglycaemic events (and fear of these events), which are not currently 
available in the literature.  Finally, while the EQ-5D is collected in the cardiac arrhythmias audit 
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(currently collected in patients undergoing ablation procedures only), it is recommended that this is 
extended to include all patients. 
 
There are just three of the 13 conditions where the EQ-5D is not recommended for use: 
 Schizophrenia: where the WEMWBS is recommended, to be replaced by the ReQOL in due 
course 
 Dementia: where the DEMQOL –U is recommended 
 Epilepsy: where the PedsQLTM is recommended due to the candidate population being 
paediatrics. 
 
Additional research would be required in these conditions to enable these data to be used to 
generate QALYs in economic models.  However, these data would still provide useful information for 
comparisons across providers.   
 
PROMs: With the exception of epilepsy which is a paediatric population only, the EQ-5D-5L is 
recommended to compare providers or conduct economic evaluations, noting the following points: 
 
 include the new five level version of the EQ-5D in patient questionnaires to inform 
preference-based utility values for economic models and to compare providers (IBD, 
diabetes (with vision bolt-on), bowel cancer, head and neck cancer, psychological therapies, 
all cardiovascular conditions) 
 include additional condition specific PROMs in addition to the EQ-5D (PRO2/3 in IBD, EORTC 
QLQ-C30 in bowel and head and neck cancer (with corresponding condition specific 
modules), PHQ-9/GAD-7 and ReQOL in psychological therapies) 
 for paediatrics, include the PedsQLTM and age-related generic preference-based measures 
(CHU-9D, HUI2 and EQ-5D-Y) in the patient questionnaires to inform preference-based utility 
values for economic models and to compare providers (IBD, epilepsy and possibly diabetes 
depending on prevalence of paediatrics) 
 
Mandatory fields to inform economic evaluations 
Condition Severity: Many of the economic models require some assessment of condition severity 
either to stratify patients or to link to changes in HRQoL.  In many of the conditions clinical severity 
would also be a useful measure to case-mix patients when comparing across providers for example 
when assessing surgical success rates or mortality. Recommendations include: 
65 
 
 
 Collect CDAI or CAI in IBD, Dukes’ stage in bowel cancer, mucositis grade and information on 
lesions in head and neck cancer 
 Collect severity and frequency of seizures in epilepsy 
 Collect BCVA or visual acuity scores in diabetes  
 Collect MMSE and ADL in dementia 
 
Interventions: It is not clear if the details of current pharmaceutical interventions are collected in 
many of the audits and information on the type and dose of intervention would be required to 
compare the cost-effectiveness of these interventions.  In some of the conditions the known side-
effects of the pharmaceutical interventions are particularly potent and can have a considerable 
detrimental effect on HRQoL.  Collecting this information on patients treated in routine clinical 
practice would add considerably to the current evidence base in terms of quantification of the full 
effects of these interventions.  Similarly it is not clear if all the information that would be required to 
compare provider success rates relating to surgical interventions and radiotherapy is collected as 
mandatory information in all the audits.  Specific and generic recommendations relating to which 
information should be collected include:  
 
 current pharmaceutical therapy (IBD, epilepsy, PCI, cardiac arrhythmia) 
 response and or relapse rates for pharmaceutical treatments (generic) 
 adverse events associated with pharmaceutical interventions (generic but in particular, 
biologics in IBD, chemotherapy in bowel cancer and head and neck cancer, antipsychotic 
drugs in schizophrenia, anti-arrhythmic and anticoagulant drugs in cardiac arrhythmias) 
 surgical success rates and associated complications (IBD, bowel cancer, head and neck 
cancer, CVD surgical procedures) 
 radiotherapy success rates and adverse events (bowel cancer, head and neck cancer) 
 procedure details: Number and type of stents; type of vascular access (coronary angioplasty) 
 cardiac event rates on follow-up (cardiac surgery) 
 
Clinical events: All the conditions reviewed are chronic /progressive conditions and, in many, 
patients are at risk of condition related clinical events.  Event rates in the existing economic 
evaluations are often derived using risk functions based on clinical measures such as blood pressure, 
lipid levels and weight.  While it is recommended that the audits are checked to ensure that the 
appropriate clinical markers are collected as mandatory fields, additional information in the 
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following areas would be informative both when comparing providers and when conducting 
economic evaluations: 
 
 cardiovascular and cerebrovascular events (occurrence, type and severity of disability 
following event in diabetes, coronary angioplasty, cardiac surgery, ACS) 
 cause of death (IBD, epilepsy, diabetes, bowel cancer, head and neck cancer, heart failure, 
coronary angioplasty, cardiac surgery) 
 
 
Future research 
Many of the suggestions for future research are generic across the conditions: 
 assess the psychometric properties of the recommended PROMs using the data collected in 
the respective audits (all audits) 
 synchronise the timing of collection of clinical and HRQoL evidence to enable the HRQoL 
data to be used in economic evaluations (all audits) 
 conduct a detailed review of data collected in the current audits with a view to informing 
which variables should be collected as mandatory evidence to inform future economic 
evaluations (all audits). 
 
Individual condition specific recommendations and areas for future research include: 
 Consider collaborating with the developer of the PedsQLTM to develop an associated 
paediatric preference-based measure (IBD, epilepsy) 
 Conduct mapping functions between clinical variables/PROMs and preference-based 
measures to enable the data to be used in economic evaluations (IBD, diabetes, bowel 
cancer) 
 Generate new preference-based weights for EQ-5D vision bolt-on (diabetes) 
 Explore the effects of hypoglycaemic events on HRQoL (diabetes) 
 Ensure all therapists use a common set of measures, which match those adopted in the NHS 
Outcomes framework (psychological therapies) 
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Limitations 
Limitations relating to WP1.1 
Whilst WP1.1 provides a thorough overview of the literature relating to the psychometric properties 
of the EQ-5D in the 13 NCA conditions, there are a number of limitations which should be borne in 
mind.  
 
1) The review methodology was a review of reviews. There are weaknesses inherent in such reviews, 
which apply: 
 A review of reviews is always subject to greater error as data has been extracted twice: 
once by original review authors, then again for the review of reviews.  
 Review of reviews depend on the quality of the study design, and on the accuracy in the 
implementation and reporting of the original review team 
 Not all information needed to assess the quality of searches and data extraction is always 
reported. 
2) Other limitations specific to this review of reviews include: 
 Interpretations and categorisations of psychometric properties vary across the literature, 
and in some cases the definitions may not always have matched the inclusion criteria and 
definitions of WP1.1. Without reanalysing every review, it was not possible to always omit 
the data that did not match our definitions. 
 In some cases, it was not possible to ascertain whether the conclusions of the authors were 
supported by the evidence, due to a lack of primary data being presented in the review. 
Where this was particularly problematic, data was extracted from the primary studies. 
However, this was only done for severe cases of lack of transparency, and some lack of 
clarity may persist in some cases.  
 Some reviews analysed data in a different manner than was planned for WP1.1, and 
sometimes their methods were not transparent.  
 A combination of the above three points (definitions of psychometric; lack of primary data 
presentation; differences in analysis methods), in combination with inevitable subjectivity in 
synthesis may have resulted in different conclusions having been drawn by the review 
authors than we would have drawn ourselves. Where such issues were considered very 
problematic, however, a re-analysis of the review data, sometimes including primary data 
extractions, was conducted.  
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 Each review conducted searches differently. Whilst the majority were judged to be
adequate, there was not a consistent approach across reviews, and some searches may have
been more comprehensive than others.
 Not all reviews performed quality assessment of primary studies, and we did not include this
formally in WP1.1 either. A consensus on how to quality assesses studies in psychometric
analyses has not yet been achieved. Some methods simply look to the number of missing
data points, and the match of the patient characteristics with the population of interest.
Both of these types of quality have been considered in our synthesis, but a remarkable lack
of information relating to missing data points (many primary studies reported completers
only) made a meaningful assessment of quality of the included studies impossible both
within our own review, and within reviews we have reported. Even where reviews did
perform quality assessment, it is rarely clear how this was integrated into review
conclusions.
3) Other limitations
The paediatric reviews in epilepsy and IBD were unfortunately not comprehensive due to time 
constraints. The search terms included known paediatric preference based measures and as such, 
not all evidence will have been identified relating to other condition specific or generic measures 
that are not preference based.  
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Limitations relating to WP1.2 
A full review, or a review or reviews, of all generic or conditions specific measures was not possible 
for WP1.2 within the time available. Searches were instead limited to searching for 
recommendations relating to PROMS in a few key sources for each condition. In most cases, these 
sources were not evidence based, and the rationale for the choice of one measure over another not 
always clear. As a result, we have, in large part, relied on the expert-knowledge of ongoing research 
and current DH programmes to inform the recommendations for WP1.2 in this report. Whilst this is 
not evidence-based, it is arguably a more suitable and integrated approach in the given 
circumstances, producing prescient recommendations that will be relevant for longer. 
Limitations relating to WP1.3 
Due to time constraints, an exhaustive strategy was not used to identify ongoing or scheduled 
research exploring the use of PREMs or PROMs in the different NCAs.  In many cases, the contacts at 
the individual Audits were asked if they knew of any ongoing research in these areas.  If required, it 
is possible to go back to this question to develop a more exhaustive strategy to identify any planned 
or ongoing research in more detail. 
In addition, the recommendations for mandatory fields within the individual audits are based on the 
questionnaires used, rather than an in-depth review of the evidence collected.  Consequently the 
recommendations for additional fields are indicative only. 
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APPENDIX C: INFLAMMATORY BOWEL DISEASE (see separate document) 
APPENDIX D: EPILEPSY (see separate document) 
APPENDIX E: DIABETES (see separate document) 
APPENDIX F: BOWEL CANCER (see separate document) 
APPENDIX G: HEAD AND NECK CANCER (see separate document) 
APPENDIX H: PSYCHOLOGICAL THERAPIES (see separate document) 
APPENDIX I: SCHIZOPHRENIA (see separate document) 
APPENDIX J: DEMENTIA (see separate document) 
APPENDIX K: CARDIOVASCULAR DISEASE (see separate document) 
APPENDIX A - Methods see link - Appendix A - Methods
APPENDIX B - Searches  see link - Appendix B - Searches 
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APPENDIX L: AGE AND COMORBIDITIES 
Additional detail on information relating to the ages and comorbidities described in the existing reviews. 
Table L1: Information on age and comorbidities as reported in the reviewsa  
Condition
b
Age in years Comorbidities Comments 
IBD 
New review 
Mean age ~42 (SD ~12) No exclusions were reported in the primary 
studies 
Given the relatively large variation in age, and the fact 
that specific exclusions relating to comorbidities were 
not reported, it is likely that subjects with comorbidities 
were included. 
Consequently the results should generalise across a 
broad range of ages and subjects with comorbidities. 
Diabetes 
Reanalysis of 
Janssen et al 
Mean age range: 55-67 4/16 studies did not report any exclusions in 
their recruitment criteria 
1/16 selected only diabetics with high risk of 
vascular disease 
11/16  studies excluded some of the 
following: Psychological illness (7); cardiac 
disorders (1; hepatic disease (1; pregnancy (1; 
severe uncontrolled hypertension (1); 
systemic corticosteroid treatment (1); 
recreational drug/alcohol abuse (2); any 
serious, unstable/acute medical condition (4); 
neurological disorders (4); other pain 
condition (4); skin condition (3); amputation 
(1); macular degeneration &/or glaucoma (1); 
hearing difficulty (1); HIV/AIDS (1) 
Given the mean age ranges, comorbidities are very likely 
in the four studies that did not report any exclusion 
criteria. Of studies that were selective, one actively 
recruited those with diabetes and high risk of vascular 
disease, and did not list any other exclusion criteria. Of 
the remaining 11, there were exclusions of some 
comorbidities. Mostly, this occurred in only a few 
studies. However, psychological illness has been 
excluded from seven studies, usually for practical 
reasons. As such, the evidence base may not be 
generalizable to patients with serious psychological 
conditions.  
Mental health 
Peasgood et al 
Mean age range: 40-74 
Minimum reported:17 
Maximum: not reported 
6/31 of the studies reported specific mental-
health related exclusions such as history of 
mania, schizophrenia or suicide intention. 
1/31 of the studies excluded anyone with a 
‘comorbid condition’[Aydemir et al, 2009] 
One study (mean age 74.1) concluded the EQ-5D was 
less responsive in older patients as the EQ-5D was less 
responsive than the BDI-II. 
However, several of the studies recruited subjects 
representative of the general population, thus the 
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No other exclusions were reported for the 
balance (24/31) of studies. 
1 study reported 59% in primary care have ≥ 1 
comorbidity[Sobocki 2007] 
results should generalise across a broad range of ages 
and subjects with comorbidities.  
Dementia 
Hounsome et al 
Mean age range: 61-81 No exclusions were reported in Hounsome Given the mean age range, it is likely that there are 
subjects with comorbidities in at least some of the 
studies and the results should generalise across. 
Schizophrenia 
Pappaiannou et al 
Mean age range: 29-41 
Minimum reported:18 
Maximum reported: 80  
No exclusions were reported in Pappaiannou Given the age range, it is likely that there are subjects 
with comorbidities in at least some of the studies and 
the results should generalise across. 
Bowel cancer 
Longworth et al 
Not reported in Longworth No exclusions were reported in Longworth No reporting or discussion of co-morbidities or age for 
review or from individual studies. 
Cardiovascular 
disease 
(updated review) 
Mean age range: 55-69 
Minimum reported:17 
Maximum reported: 88 
3/13 studies excluded older subjects 
(>60 n=1 study, >80 n=2 studies) 
7/13 studies excluded younger subjects 
(<17 n=1 study, <18 n=2 studies, <30 n=2 
studies, <35 n = 2 studies) 
Exclusions included:  
a) Age (see adjacent cell)  
b) Cardiovascular condition: 
duration of time since previous cardio 
event or intervention,  
severity of cardiovascular condition (i,.e. 
New York heart failure class IV) 
Given the reported age ranges, and exclusion criteria, it 
is likely that there are subjects with comorbidities in at 
least some of the studies. 
Consequently the results should generalise across a 
broad range of ages and subjects with comorbidities. 
a 
The data were extracted as reported in the reviews, and this evidence was not reported for all the individual studies.  
b 
Epilepsy: NCA for children hence presence of 
comorbidities is not applicable for the vast majority; Head and neck cancer: no studies were identified in the searches. 
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